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ABSTRACT
HYPERSENSITIVITY ADVERSE EVENT REPORTING IN CLINICAL CANCER TRIALS:
BARRIERS AND POTENTIAL SOLUTIONS TO STUDYING ALLERGIC EVENTS ON A
POPULATION LEVEL
by
Christina Eldredge
The University of Wisconsin-Milwaukee, 2020
Under the Supervision of Professor Timothy Patrick

Clinical cancer trial interventions are associated with hypersensitivity events (HEs) which are
recorded in the national clinical trial registry, ClinicalTrials.gov and publicly available. This
data could potentially be leveraged to study predictors for HEs to identify at risk patients who
may benefit from desensitization therapies to prevent these potentially life-threatening reactions.
However, variation in investigator reporting methods is a barrier to leveraging this data for
aggregation and analysis. The National Cancer Institute has developed the CTCAE classification
system to address this barrier. This study analyzes the comprehensiveness of CTCAE to
describe severe HEs in clinical cancer trials in comparison to other systems or terminologies.

An XML parser was used to extract readable text from adverse event tables. Queries of the
parsed data elements were performed to identify immune disorder events associated with
biological and chemotherapy interventions. A data subset of severe anaphylactic and
anaphylactoid events was created and analyzed.

1,331 clinical trials with 13088 immune disorder events occurred from September 20, 1999 to
March 2018. 2409 (18.4%) of these were recorded as “serious” events. In the severe subset,
MedDRA terminology, CTCAE or CTC classification systems were used to describe HEs,
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however, a large number of studies did not specify the system. The CTCAE term “anaphylaxis”
was miscoded as “other (not including serious)” in 76.2% of events. The CTCAE classification
system severity grades levels were not used to describe any of the severe events and the majority
of terms did not include the allergen and therefore, in dual or multi- drug therapies, the etiologic
agent was not identifiable. Furthermore, collection methods were not specified in 76% of
events.

Therefore, CTCAE was not found to improve the ability to capture event etiology or severity in
anaphylaxis and anaphylactoid events in cancer clinical trials. Potential solutions to improving
CTCAE HE description include adapting terms with a low percentage of HE severity miscoding
(e.g. anaphylactic reaction) and terms which include drugs, biological agents and/or drug classes
to improve study of anaphylaxis etiology and incidence in multi-drug cancer therapy, therefore,
making a significant impact on patient safety.
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CHAPTER ONE: INTRODUCTION
This study aims to analyze the feasibility to study severe hypersensitivity events secondary to
clinical cancer trial drug and biological agent interventions, identify barriers to conducting
population-level analysis of these adverse events, and suggest potential practical solutions to
address the barriers. A preliminary analysis of publicly available data in clinicaltrails.gov
revealed significant challenges to population-level analysis of hypersensitivity events across
clinical trials due to variation in clinical trial reporting data collection methods, lack of
information on the etiology (antigen) of the event, temporal information, and lack of granularity
(lower level terms) available to code hypersensitivity allergic events in certain controlled
terminologies and classification systems. Furthermore, the complex nature of cancer
interventions with several drugs and/or agents involved in one clinical trial arm compounded the
problem of characterizing the hypersensitivity events. The National Cancer Institute has
developed five severity “grade” levels with their Common Terminology Criteria for Adverse
Events (CTCAE) classification system (National Cancer Institute, 2006) to address this barrier,
however, the preliminary analysis of the data revealed that these grades are not regularly used in
reporting hypersensitivity events in this dataset. (Eldredge, Singavi, Lam, Gallagher, & Luo,
2018) Furthermore, the literature notes the unique challenges of using controlled terminology or
classification systems to capture hypersensitivity events, especially allergic events. (Goss, et al.,
2013) Therefore, it is hypothesized that lack of granularity with regards to documenting the
antigen and accurate identification of severity in adverse hypersensitivity event reporting in dual
and multi drug and/or biological agent therapy interventions hinders the ability to identify and
study the incidence of these events, specifically in a case study of severe anaphylaxis and
anaphylactoid reactions with cancer therapy interventions, across clinical trials.
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To test this theory, this study will first analyze the current state of hypersensitivity adverse event
reporting in cancer clinical therapy using data from clinicaltrials.gov. The scope of the study
will be focused on hypersensitivity events which are categorized as immune disorder events by
the National Cancer Institute (NCI) and a case study of a subset of severe hypersensitivity
adverse events, specifically anaphylactic and anaphylactoid events which are severe immediate
life-threatening adverse events. Variation in terminology use and gaps in reporting the antigen
etiology (referred to as “allergen” in reference to purely allergic events in this study) and adverse
event severity will be analyzed to inform future secondary use of the data for population level
analysis, future terminology or classification system improvements, and semantic mapping of
hypersensitivity events.

Cancer incidence is increasing and may surpass diseases of the heart as the most common cause
of death in the United States (National Vital Statistics, 2017). New initiatives, such as the
National Cancer Institute Cancer Moonshot, aim to expedite and streamline research to find a
cure for this devastating disease (Institute, 2018). As a result, several new anti-cancer therapies
are being approved by the U.S. Federal Food and Drug Administration through a “fast track
process” (U.S. Food & Drug Administration, 2018). Furthermore, new research and
development is increasing the number of available drugs and therapies, especially biological
immune therapies. However, cancer therapy, especially chemotherapy and biological therapies,
are known to be associated with severe adverse events, especially severe hypersensitivity events,
often referred to anaphylaxis or anaphylactoid reactions. (Giavina-Bianchi, Patil, & Banerji,
2017). Despite this, few predictive risk factors are known, however, several possible risk factors
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for severe anaphylactic reactions are being studied such as age, gender, vigorous exercise and
certain drugs and biological agents. (Worm, et al., 2018) Furthermore, new methods for
treatment such as drug desensitization therapy can be used to prevent these potentially lifethreatening events, however, prior risk identification would inform potential candidates.
(Bonamichi-Santos & Castells, 2018)

ClinicalTrails.gov is one of the largest databases of clinical trial data, both publicly and privately
funded. (ClinicalTrials.gov, 2018) This registry has steadily grown since the year 2000,
incorporating increasing requirements for clinical trial outcomes and adverse event reporting.
Currently, all adverse events, including hypersensitivity events, in ClinicalTrails.gov, are
recorded by the clinical trial investigator team using their collection assessment method and
terminology or classification system of choice. (U.S. National Library of Medicine, 2017) Since
investigators vary in their data collection assessment methods and choice of controlled
terminology for data reporting, significant barriers exist to the secondary analysis of this data on
a population level to support studies on risks factors for hypersensitivity events in cancer trials.
In addition, the comprehensiveness of each terminology, to capture allergy event severity,
allergen, acuteness and recurrence varies significantly, compounding the problem. (Goss et al,
2013) In this study, adverse allergic events were extracted from semi-structured tables in
ClinicalTrials.gov from the time period of 1999 through 2018 using an XML parser. The
terminology used to describe these events was analyzed for the presence of descriptors
specifically: allergen, severity, acuteness and reoccurrence. Additionally, the collection and
assessment method used by each investigator was examined.
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The following research questions and hypotheses was used in analyzing the data:

Research Question:
Is the use of National Cancer Institute CTCAE Classification System, with its ability to grade
severity of adverse events, improving the ability to aggregate clinical trial data to study the
incidence, etiology and severity of severe hypersensitivity events secondary to cancer biological
and/or chemotherapeutic agents on a population level (across clinical trials) in comparison to the
use of MedDRA?

Hypothesis #1:
The ability to accurately record severity of anaphylactic and anaphylactoid events secondary to
cancer biological and/or chemotherapy agents is improving with the use of the CTCAE
classification system and its emphasis on severity grades in comparison to MedDRA.

Hypothesis #2:
Terms used to describe severe anaphylactic and anaphylactoid events recorded in the dataset of
clinical cancer trials from ClinicalTrials.gov rarely (<5% of events) include the antigen
responsible for the event which hinders the ability to study incidence of drug and biological
agent induced hypersensitivity events when the clinical trial intervention includes multiple drugs
and/or multiple therapeutic agents. In other words, there is no statistical difference between the
types of terminologies or classification systems used regarding the inclusion of the antigen
within the severe hypersensitivity event term.
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Hypothesis #3:
Over 25% of the severe anaphylactic and anaphylactoid events have not been recorded using a
systematic assessment method which could result in underreporting of events.
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CHAPTER TWO: BACKGROUND AND LITERATURE REVIEW

Definitions and classification of adverse drug reactions
Adverse drug reactions (ADRs) fall under adverse drug events (AEs). The FDA Guideline for
Industry, “Clinical Safety Data Management: Definitions and Standards for Expedited
Reporting”, defines as adverse event as the following: “Any untoward medical occurrence in a
patient or clinical investigation subject administered a pharmaceutical product and which does
not necessarily have to have a causal relationship with this treatment.” (FDA, 1995) The FDA
further breaks down this category into serious and severe events. Severity of events are
documented by intensity (e.g. mild, moderate, or severe), in contrast to seriousness of the event,
which are coded by the patient outcome. (FDA, 1995)

In the academic allergy community, adverse drug reactions (ADRs) are defined by the Joint Task
Force on Practice Parameters (which includes the American Academy of Allergy, Asthma and
Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council
of Allergy, Asthma and Immunology) as any inadvertent drug reactions which are not intentional
abuse or overdose, the result of an error in medication administration or “therapeutic failures”.
The incidence of ADRs is approximately 10% in hospitalized patients and 7% in outpatients.
(Schnyder & Pichler, 2009).

Hypersensitivity events (HEs) are types of adverse drug reactions which are unpredictable and
may not be dose related, however, these reactions are “characterized by objectively reproducible
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symptoms and/or signs initiated by exposure to a drug at a dose tolerated by normal individuals”.
(Giavina-Bianchi, Patil, & Banerji, 2017) In addition, these reactions can be caused by immune
mediated or non-immune mediated mechanisms. (Stone, Phillips, Wiese, Heddle, & Simon,
2014) Both types of HEs, immune and non-immune mediated, may be sudden and severe.
(Stone, Phillips, Wiese, Heddle, & Simon, 2014), According to Gomes et al, drug
hypersensitivity drug events comprise approximately a third of adverse drug reactions. (Gomes
& Demoly, 2005)

Drug allergy an immune mediated hypersensitivity event, which is defined by the Joint Task
Force as “an immunologically mediated response to a pharmaceutical and/or formulation
(excipient) agent in a sensitized person.” (Drug Allergy: An Updated Practice Parameter, 2010)
A severe potentially life-threatening form of drug allergy is referred to as an anaphylactic
reaction or anaphylaxis. This is in contrast to pseudo-allergic reactions, which are often referred
to as “anaphylactoid reactions” and are not caused by IgE-mediated immune mechanisms. (Drug
Allergy: An Updated Practice Parameter, 2010) In 2018, the World Allergy Organization
recommended these types of reactions be referred to as “nonimmune anaphylaxis”. It may seem
contradictory to categorize these reactions in the “immune disorder” category in the adverse
events tables, however, these reactions do involve immune related mechanisms such as mast
cells (which release histamine) and basophils without an “immune complex formation”
(antibody-antigen complex). (World Allergy Organization, 2018) Severe hypersensitivity
reactions are commonly associated with cancer therapeutic agents such as monoclonal antibodies
and chemotherapeutic agents as well as contrast agents. (World Allergy Organization, 2018)
Figure 1 below displays the hierarchy of adverse drug events.
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Anaphylactic type Reactions
The sudden and severe form of an allergic reaction is often referred to as anaphylaxis. (Stone,
Phillips, Wiese, Heddle, & Simon, 2014) Although, this term had been previously poorly
defined prior to 2010 and continues to be debated in some allergy circles. The definitions used
to describe anaphylaxis include the words “serious” and “rapid onset” and often refer to the
potential of shock and death as an outcomes. (American Academy of Allergy, Asthma &
Immunology, 2020) (Simons, Ardusso, Bilo, Bilio, & et al., 2011). (National Cancer Institute,
2020) The World Allergy Organization guidelines published in 2011 lists the criteria for a
“highly likely” diagnosis of anaphylaxis based on the timing of the onset of symptoms (sudden),
the types of symptoms involved in the reaction, and whether or not the patient has been exposed
to a “known allergen”. (Simons, Ardusso, Bilo, Bilio, & et al., 2011) The generally accepted
symptoms of this severe adverse event include: rash, wheezing, stridor, difficulty breathing,
syncope, abdominal systems, and oral pharyngeal edema (swelling). (American Academy of
Allergy, Asthma & Immunology, 2020) (Simons, Ardusso, Bilo, Bilio, & et al., 2011) The NCI
Thesaurus definition also notes the physiology of the reaction in which histamine release occurs
in response to allergen exposure. The term is listed as a lower level term (LLT) and as a disease
or syndrome semantic type. (National Cancer Institute, 2020)

Anaphylaxis is increasing in incidence, currently thought to be approximately 4-50/100,000
person-years (Kim et al, 2014). Additionally, hospital admissions with a diagnosis of
anaphylaxis have been increasing in number (Turner et al, 2015), which likely indicates
increasing incidence of severe allergic reactions or could be due to improved reporting. Accuracy
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and standardized reporting of HEs, especially immediate allergic, events in cancer clinical trials,
allows for population level studies of the potential risk factors for these events. Population level
studies, e.g. studies conducted using population-level healthcare databases, can improve the
power of studies, especially in cases of rare forms of cancer or studies which may have low
enrollment. Analysis of the potential risk factors involved in HEs aids in development of
prevention and treatment protocols to improve patient safety. (Siverendran S, 2014)

Figure 1. Adverse Drug Reaction Types (FDA, 1995) (Vultaggio & Castells, 2014)
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Hypersensitivity events in clinical cancer therapy
In addition to the increase in incidence of cancer in the population as discussed above, there is
also a projected further increase in new cancer diagnoses of approximately 70% within the next
twenty years. (Giavina-Bianchi, Patil, & Banerji, 2017) Several new therapies are developed
each year. Therefore, the risk of hypersensitivity events during cancer treatment, with the use of
chemotherapy and biological agents, will likely increase. In fact, a study of mortality data from
the U.S. National Center for Health Statistics (NCHS) determined anti-neoplastic agents (cancer
medications) as the third most common cause of fatal drug induced anaphylaxis. (Jerschow, Lin,
Scaperotti, & McGinn, 2014)

Cancer Diagnostic and Therapeutic Agents
Cancer drugs and biological agents are commonly used in cancer treatment, and most of these
drugs and agents have been associated with hypersensitivity events. (Lee, Gianos, &
Klaustermeyer, 2009). Cancer therapy can be divided into several types of treatments which,
according to the NCI, include the following: chemotherapy, immunotherapy, hormone therapy,
radiation, targeted therapy, stem cell transplants, precision medicine and surgical treatments.
This study will focus on chemotherapy (drug therapy) and immunotherapy (biological therapy).
Immunotherapy can be used in precision medicine and target therapy. (NCI, 2015)

Several studies have noted the presence of hypersensitivity events to chemotherapy agents such
as the platinum class of drugs which includes carboplatin. In the case of platinum agents, the
adverse hypersensitivity events can be dose dependent, in contrast to taxanes and monoclonal
antibodies which generally occur during the first or second infusion. (Lenz, 2007) Therefore,
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research on predictors associated with the class of drug in an intervention can have a significant
impact on the need for preparation and prevention of severe hypersensitivity events.

Biological therapies: Immunotherapy and targeted therapies
Biological agents differ from chemotherapy as these agents are derived from living organism or
the substances are created in a laboratory to resemble the natural substances and used to
eliminate cancer cells during therapy. (Dana-Farber Cancer Institute, 2017) According to the
NCI, there are several types of biological therapies which are used to treat cancer, which are
generally divided into the following categories by the NCI: Immune checkpoint inhibitors,
immune cell therapy, therapeutic antibodies, therapeutic vaccines, and immune-modulating
agents (NCI, 2018) Biological agents are associated with severe hypersensitivity infusion
reactions and these reactions can be fatal.

Immunotherapy, which is a type of biological therapy, approaches the treatment of cancer from a
different mechanism of action than chemotherapy. Immunotherapy works via either attacking
the cancer cells or by mechanisms which stimulate the patient’s own immune system to aid in
targeting the cancer cells within the patient’s body (NCI, 2018) (Dana-Farber Cancer Institute,
2017) Therapeutic antibodies are an example of a type of targeted cancer therapy, which are
created in a laboratory to bind to cancer molecules to block the replication of cancer cells in the
patient. (NCI, 2018)
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Chemotherapy and Hypersensitivity Reactions
In contrast to biological therapies, chemotherapies have been the mainstay of cancer therapy for
decades. These agents treat cancer by interfering with the cancer cell’s ability to divide,
therefore, inhibiting cancer growth. Unfortunately, these drugs have several adverse effects and
can also affect the growth of normal cells, a common manifestation of this is hair loss. In
addition, certain classes of chemotherapeutic drugs are frequently associated with adverse
hypersenstivitiy events, and as noted above, some may correlated with the number of drug
infusions. However, in certain drug classes, de-sensitization methods may be used prior to
administration to the patient to minimize these adverse hypersenstivity events in at-risk patients.
(Guitart, 2014) Therefore, using data-driven approaches to study clinical trial data can
potentially aid in identifying the most likely etiologic agents and the patients at most risk of a life
threatening response to drug administration.

Cytokine release syndrome
A severe adverse immune response associated with biological and chemical agents, e.g.
monoclonal antibody (mAB) therapy, for cancer patients is cytokine release syndrome (CRS).
This is an adverse immune event caused by the sudden release of immune substances referred to
as “cytokines” from cells targeted and/or affected by the antibody therapy which result in several
symptoms described in figure 2 below. However, the exact mechanism of how this occurs is not
yet completely understood. (Shimabukuro-Vornhagen, et al., 2018) CRS may in some instances
be referred to as an “infusion reaction” and can vary in severity from mild to severe (life
threatening immune events). (Breslin, 2007) According to the NCI, most of these events are
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mild to moderate in severity, however, some events can be life-threatening. (National Cancer
Institute, n.d.)

Figure 2. Etiology and Symptoms of Cytokine Release Syndrome

An important point to highlight here is the similarities in terminology descriptive needs between
CRS and anaphylactic events. Both events may vary in severity and have been associated
directly with specific allergens. Additionally, both events have several symptoms which may be
recorded separately and not specifically as the syndrome itself, e.g. chills or wheezing.

Brief History of ClinicalTrials.gov
The Food and Drug Administration Modernization Act of 1997 (FDAMA) included a section
requiring the National Institute of Health to create a public registry of clinical trials, specifically
trials which involved drugs treating life-threatening health conditions (U.S. National LIbrary of
Medicine ClinicalTrials.gov, 2018). The legislation is intended to improve public access to
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health information on clinical trials of experimental therapies. In 2000, the ClinicalTrials.gov
website was launched. (Press Release: National Institutes of Helath Launches
"ClinicalTrials.gov", 2000) In 2005, further legislation was published by the International
committee of Medial Journal Editors to require trial registration “as a condition of publication”.
(ClinicalTrials.gov, 2018) The following year, the World Health Organization (WHO)
recommended that all clinical trials be registered. WHO created their own platform, which
incorporates data from ClinicalTrials.gov. (World Health Organization, 2019)
In 2007, Public Law 110-85 Sec. 801, “Expanded Clinical Trial Registry Data Bank”, was
passed by Congress requiring expansion of the current data entry requirements for this clinical
trial registry and public online access. Required reporting included: clinical trial title, summary,
study type and design, primary and secondary outcomes, demographic data, dates. (Congress,
2007) In 2009, sponsors of clinical trials were required to enter adverse event reports into
ClinicalTrials.gov. (Neuer, 2009)

Figure 3. Timeline of ClinicalTrials.gov Milestones
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Cancer Adverse Event Reporting in ClinicalTrails.gov
Clinicaltrials.gov uses the following definition for adverse events:
Any untoward or unfavorable medical occurrence in a participant, including any
abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or
disease, temporally associated with the participant’s participation in the research, whether
or not considered related to the participant’s participation in the research.
(ClinicalTrials.gov, 2018)

Adverse event types recorded in Clinicaltrails.gov are entered into the following three adverse
event tables by the clinical trial investigator: All-cause mortality; Serious adverse events (AEs);
Other (Not Including Serious) AE . (ClinicalTrials.gov, 2018)

In clinicaltrials.gov, adverse event reporting is not required to follow a specific standard
terminology or classification system. Rather, adverse event data is entered into the three tables
using the investigators standard vocabulary or classification system of choice. However, there is
a requirement for investigators to enter adverse event reporting into semi-structured tables which
follow an organ system category approach used by the Medication Dictionary for Regulatory
Activities (MedDRA). (Goss, et al., 2013)

Adverse event data elements include the following: Time frame, description, source vocabulary
name, collection approach (systematic vs. non-systematic), total number affected, total number at
risk, and organ system. Investigators submit this data into semi-structured “Serious Adverse
Event” and “Other (Not Including Serious)” tables organized by organ systems. Please see the
example screen shot in Figure 4 below of an “Other (Not Including Serious)” adverse event
result table.
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Figure 4. Screenshot of Other (Not Including Serious) Adverse Events Table

(U.S. National Library of Medicine, 2017)
ClinicalTrails.gov data element definitions are listed on their website and can be retrieved at:
https://prsinfo.clinicaltrials.gov/results_definitions.html#AdverseEvents
Currently, the National Library of Medicine has begun an effort to “modernize” this website and
database in order to improve its usability for investigators, patients, family members and
researchers who use this data for secondary population level research. (U.S. National LIbrary of
Medicine, 2020) This project will also provide necessary feedback to support this project.
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Medical Terminologies for Adverse Drug Reporting
In the 1990’s, the need for more standardized reporting of clinical trial outcomes and adverse
events was evident to researchers and journal editors who responded to this need with the
Consolidated Standards of Reporting Trials (CONSORT) statement. (Peron J, 2012) The
specialized need for improvement in the comprehensiveness and quality of reporting of adverse
events and outcomes in randomized controlled trials, especially in cancer clinical trials where
potential drug toxicities and narrow therapeutic indexes are common, was apparent. (Ghimire S,
2014)

To address this gap in standardized clinical trial reporting, the National Cancer Institute
developed a controlled classification system specifically to record adverse events in clinical
cancer trials called Common Toxicity Criteria (CTC) created in 1983, and updated with a version
2 prior to the change in name. (Trotti, et al., 2003) In 2006, the Common Terminology for
Adverse Events or CTCAE version 3.0 was published, CTC was rename CTCAE removing
“toxicity” from its name. (Trotti, et al., 2003) This terminology is organized according to the
MedDRA system organ class. Adverse events each have a specific definition and the events are
graded based on severity criteria. The latest version for cancer adverse reactions mapping
(version 5) is current available on the National Cancer Institute website (NCI). According to the
CTCAE quick reference guide, CTCAE version 5 not only uses the same system organ
classification as MedDRA, this version has also incorporated elements of MedDRA’s
terminology. (U.S. Department of Health and Human Services, 2017)
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Common Terminology Criteria for Adverse Events in Cancer Clinical Trials
The Common Terminology Criteria for Adverse Events (CTCAE) was developed by the
National Cancer Institute to record common adverse events in clinical cancer trials. The use of
this classification system is required for recording adverse events in any NCI funded clinical
cancer research study. The CTCAE classification system consists of twenty-eight categories of
adverse events groups by MedDRA’s System Organ Class (SOC). Each of these SOC, include
relative adverse events to the SOC and each adverse event uses grading scales based on clinical
criteria which include symptoms, signs, vitals and laboratory to classify severity. (National
Cancer Institute, 2020) (Richesson, Fung, & Krischer, 2008) The general guideline for grade
levels of severity in CTCAE is shown in Figure 3 below, however, the criteria to meet each level
is specific for the adverse event shown using anaphylaxis as an example in Table 2 below. In
order for an event to be included in a severity level, the clinical trial participant experiencing the
event should exhibit one or more of the criteria included in that grade. Therefore, it is difficult to
assess which of these criteria were present and which criteria were not present in the particular
grade level to classify the adverse event in grades 1-5. When performing large population level
studies using big data from sites such as ClinicalTrials.gov, investigators are unable to determine
the sign or symptom specifically, only the severity grade. If evidence-based medicine and
clinical research in subsequent versions of CTCAE lead to updates in the criteria necessary meet
the standard for the severity level for a particular disease or condition, the ability to aggregate
grade levels could be affected and the inclusion of the events from prior years in longitudinal
studies would require some level of mapping between the versions. (Richesson, Fung, &
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Krischer, 2008) Therefore, improving the granularity of the terms would improve data aggregate
quality.

Prior to the development of CTCAE, the NCI used the Common Toxicity Criteria (CTC) which
was developed in 1994 with version one and last updated in 2017 with version five. (EORTC,
n.d.) The two types of classification systems overlapped in use for some time, however, CTCAE
is currently more the preferred classification system used by the NCI. Both classification
systems are listed under the Cancer Therapy Evaluation Program, however, CTC has been
archived. (National Cancer Institute, 2020)

Table 1. CTCAE Grading Scale for Severity of Adverse Events
Grade

Severity Level

Description

1

Mild

Asymptomatic or mild
symptoms, no intervention

2

Moderate

3

Severe

4

Life-threatening

5

Death

Minimal or non-invasive
intervention indicated;
limits instrumental ADLs
Severe but not immediately
life-threatening;
hospitalization: limiting
self-care ADLs
Urgent intervention
indicated
Death related to AE

Reference: Adapted from “Common Terminology Criteria for Adverse Events v4.0 (CTCAE)
(U.S. Department of Health and Human Services, 2008)

Unfortunately, a cancer trial study using data from the years 2012-2013 revealed that categories
used to encode AEs and grade levels were often incorrectly coded. (Zhang, Liang, & Tannock,
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Use and misuse of common terminology criteria for adverse events in cancer clinical trials,
2016) (Zhang, Chen, & Wang, The use of and adherence to CTCAE v3.0 in cancer clinical trial
publications, 2016) Currently, CTCAE version 5 is available for download at the NIH National
Cancer Institute website. (National Cancer Institute, 2018) To our knowledge, no further study
of later CTCAE versions has been published.

CTCAE, in contrast to MedDRA, possesses the ability to code an “allergic reaction” at all five
grades, however, there is no ability to code “anaphylaxis” at the lower severity grading levels
(one and two) due to the severity of this particular condition. In CTCAE and SNOMEDCT_US,
the preferred term (PT) is “Anaphylaxis”, in comparison to MedDRA in which the PT is
“Anaphylactic reaction”. (National Cancer Institute, n.d.) Other synonyms to this term are acute
anaphylaxis, acute anaphylactic reaction, generalized anaphylaxis, systemic anaphylactic
reaction, and systemic anaphylaxis. The term “anaphylactic shock” is also used which indicates
signs and symptoms of shock, such as decreased blood flow, loss of consciousness and/or
hypoxia, were present as one or more of the symptoms. (National Cancer Institute, n.d.) Please
see Table 2 below which describes the NCI terms and their corresponding grades.
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Table 2. CTCAE Severity Scale for HE allergic type (U.S. Department of Health and Human
Services, 2017)
NCI CTCAE
v5.0

Grade 1

Grade 2

Allergic
Reaction*,
CTCAE
(C143271)

C143969
Systemic
intervention
not indicated

C144506
Oral
intervention
Indicated

Grade 3

C145125
Bronchospasm;
Hospitalization
indicated for
clinical sequelae;
Intravenous
intervention
indicated
Anaphylaxis*, n/a
n/a
C145135
CTCAE (C1
Symptomatic
43282)
bronchospasm,
with or without
urticaria; parenteral
intervention
indicated; allergyrelated
edema/angioedema;
hypotension
Cytokine
Fever with or Hypotension Hypotension
release
without
responding
managed with one
syndrome
constitutional to fluids;
pressor; hypoxia
symptoms
hypoxia
requiring ≥ 40%
responding
O2
to <40% O2

Grade 4

Grade 5

C146208
C145738
Death
Lifethreatening
consequences;
urgent
intervention
indicated
C146214
C145744
Death
Lifethreatening
consequences;
urgent
intervention
indicated

Death
Lifethreatening
consequences;
urgent
intervention
indicated

* If related to infusion, use Injury, poisoning and procedural complications: Infusion related
reaction. Do not report both.
Reference: Adaptive from the NCI CTEP Cancer Therapy Evaluation Program CTCAE v5.0
Quick Reference 5 x 7. (U.S. Department of Health and Human Services, 2017)

MedDRA and its relationship to CTCAE
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According the National Cancer Institute website’s NCI Term Browser, CTCAE is “harmonized
with MedDRA at the Adverse Event (AE) level.” (National Cancer Institute, 2020) CTCAE
draws from the high-level terms used by MedDRA’s System Organ Class (SOC) hierarchy as it
uses the same body system level classification of adverse events, e.g. immune system disorders
is the category used to classify hypersensitivity events. In contrast, MedDRA does not assign
each adverse event term a grade level based on severity. (U.S. Department of Health and Human
Services, November) Mappings of each version of CTC or CTCAE to MedDRA are available on
the NCI website. (National Cancer Institute, 2018)

Lack of consistent use of controlled terminology
“Large data sets are hindered by lack of robust utilised coding systems, with underreporting,
miscoding and many cases of “unspecified” triggers in admissions and fatality registers” (Turner
& Campbell, 2017) Lack of standards in the terms used to describe anaphylaxis and collection
methods remains a challenge to studying this type of severe adverse event on a population level
in large databases, however, this type of study has not been conducted in clinical trial data to our
knowledge. (Turner & Campbell, 2017) Effective use of terminologies and/or classification
systems to represent anaphylactic and anaphylactoid events could begin to address this
challenge, however, to compound the problem, Clinicaltrials.gov allows for any type of standard
terminology or classification system to allow for investigator flexibility when entering the
adverse events into the three AE summary tables: All-Cause Mortality, Serious Adverse Events
and Other (Not including Serious) Adverse Events. Additionally, there is no requirement to
specify which type of terminology or classification system was used. (ClinicalTrials.gov, 2018)
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Variation in Adverse Event Clinical Trial Collection Methods
Time frame, AE description, source vocabulary, and collection approach are also recorded by the
investigator. Again, investigators are not mandated to use a particular type of adverse event
collection method or terminology/classification system, rather, they are instructed to add the
information on the method and system into the adverse event table and this is latter added as a
footnote after each term (see figure 5 below in Chapter 3. Methods). The permissable values for
collection methods reported may be either systematic assessment, non-systematic assessment or
not specified. Systematic assessment as a data collection is defined by ClinicalTrials.gov as a
consistent method (e.g. protocol, questionnaire, diary, etc.) of routinely assessing clinical trial
participants for adverse events either during visits or using reporting tools, in contrast to their
definition of a non-systematic assessment method which relies primarily on patient self-reporting
and “unsolicited” with no formal methods or protocol of collecting adverse events.
(ClinicalTrials.gov, 2018) (U.S. National Library of Medicine, 2017)

Challenges in allergy documentation in EHRs as noted by Goss et al in their study of the
comprehensiveness of standard terminologies to capture allergy, a type of hypersensitivity
reaction. Only SNOMED CT was able to document lack of allergies (e.g. NKDA) as of the 2013
article publication date. Additionally, the authors found RxNorm better for drug related allergies
and UNII for food and substance allergens. The investigators note MedDRA “lacks formal
definitions to relate manifestation to causative agent or severity” and “excludes information on
drug/product terminology” which explains why the use of the RxNorm terminology system
maybe a better choice in the case of drug hypersensitivity events. (Goss, et al., 2013) This is
concerning given that MedDRA is one of the most common terminology types used in
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ClinicalTrials.gov and the basis for the categorization of the adverse event tables. Perhaps, this is
due to the easy of entering the data into the same organ system categories.

Previous Work on Evaluation of the Comprehensiveness of Terminologies in Hypersensitivity
Reporting of allergic events

Goss et al. evaluated the encoding of allergy by comparing SNOMED CT, NDF-RT, RxNorm,
UNII, and MedDRA. The group analyzed each of these controlled terminologies and how they
compared to each other with regards to their content coverage and ability to encode both the
reaction and the etiologic agent when encoding allergy events in electronic health records.
SNOMED CT was found to be the most comprehensive standard terminology (also uses postcoordination), however, RxNorm was noted to be a good method to encode drug allergens. The
authors state the challenges unique to encoding allergic reactions which include the need to code
the etiologic allergen, the symptoms/signs, the severity of the event and the addition of negative
findings (e.g. no known drug allergies or no known allergies). (Goss, et al., 2013)

Furthermore, different versions of the same controlled terminology or classification system can
drastically change the ability of the terminology or system to capture adverse events. For
example, a study of the incidence of adverse events in Bevacizumab therapy in patients being
treated for glioma using different versions of CTCAE (3.0 & 4.0) noted a large difference in the
incidence of severe hypertensive events. CTCAE version 3.0 reported 9.5% vs. 45.2% in version
4.0. (Bumes, et al., 2016) This is likely due to a change in criteria to meet the severe level of
this category.
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CHAPTER THREE: METHODS

Part 1: Creating the original dataset of hypersensitivity adverse events in cancer
clinical trials

Data Source
The data used in this study was obtained from ClinicalTrials.gov (discussed above). Semistructured adverse event tables are available for secondary study of clinical trial data. The data
used was collected from September 20, 1999 to March 2018.
The full dataset from clinicaltrial.gov was obtained in March 2018. After retrieving 255,065
datasets, filters were used to find clinical trials with recorded hypersensitivity events.
Please see below for the set of filters:
allTrials = get_trials_from_source('clinicaltrial.gov’)

# get all clinical trials

from the website
filter.filter_trials_by_valid_clinical_results(allTrials) # only selecting clinical
trials with valid adverse event/Other event results
filter.filter_by_category(categoryName = 'Immune system disorders’) # only
select the section named "immune system disorders” in adverse event reports
filter.filter_by_drug_list(drugList= drugSource.DrugList) # only select trials that
use at least one of drugs in specified drug list"
filter.filter_by_condition(conditionName = cancer_terms) # the overall report
must contain at least one cancer terms from the cancer-terms list
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Original dataset was created using NLP methods. An XML parser was created to extract
readable text data from adverse event tables from ClinicalTrails.gov.

Steps to create the drug and biological intervention terms list
1. An initial query of the data from ClinicalTrials.gov was queried was performed in
2016 to extract HEs using the following terms: Hypersensitivity, allergic
reaction, allergy, anaphylaxis, dermatitis allergic, drug hypersensitivity and
infusion reaction. After the results were reviewed, the query was expanded to
include broader category of “immune disorder”. A cancer intervention drug list
was created from the clinical trial intervention variable using a data driven
approach. (see Figure 2 below)
2. Frequency analysis of the intervention words in the clinical trial intervention
section was performed to identify the most commonly used intervention words
using for describing drug interventions
3. Words were analyzed manually and incomplete or non-intervention words were
removed. (e.g. “Na+” or “and”). The list of removed terms was archived as a
reference baseline.
4. An Oncology Fellow reviewed and removed non-chemotherapy agents or
chemotherapy agents that are not currently used in cancer therapy
5. Duplicate interventions were removed.
6. Cancer drugs were classified by drug class in consultation with the Oncology
Fellow
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7. Cancer trial interventions were then split into two broad groups: Single therapies
and Combination drug therapies.
8. Another query for hypersensitivity reactions was performed using a join with this
newly created common cancer drug intervention term list to search the original
database of clinical trial adverse reactions (#1) again (iterative process).
See Appendix A for complete list of drugs and biological agents.

Figure 5. Original data pipeline

Part 1a: Data Quality Analysis
1. Data was analyzed for spelling errors and use of abbreviations. This were
corrected.
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2. NCI trial arms were reviewed while recording terminology types manually,
randomly selected clinical trials were verified by returning to the original data in
ClinicalTrials.gov to test for accuracy of numbers of affected and at risk clinical
trial participants.
3. NLP data extraction errors were returned to the lab for analysis and correction of
the data pipeline and NLP methods.
4. After data corrections, random records were again selected for a final data quality
check.

Part 2: Descriptive analysis of the dataset and creation of a subset of severe
events
The dataset was analyzed descriptively to provide a population level view of the characteristics
of immune disorder hypersensitivity events in cancer clinical trials: Cancer types, drug
interventions, number of participants affected, number of participants at risk, number of serious
events and number of other (not including serious events).

Additionally, severe anaphylactic, anaphylactoid and grade 3-5 hypersensitivity adverse events
were identified as a subset of the original dataset. This subset of severe events was analyzed
using pivot tables in Excel. A pivot table of the data points “adverse event” and “sum of affected
number” and “sum of at-risk number” in each clinical trial arm was created. Furthermore,
another pivot table was created with the severe anaphylactic type events along with the severity
level for each event, number of clinical trial arms, number of affected participants and number of
at-risk participants. CRS events were not included in this subset as it was not possible to
determine if the events were severe due to the lack of grading of these events.
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Part 3. Terminology evaluation
The subset of severe anaphylactic and anaphylactoid type adverse events was analyzed to
determine the type of controlled terminology or classification system used to record each of these
adverse events. Unfortunately, this data point was not discretely recorded in the adverse event
tables within ClinicalTrials.gov. Instead, the terminology or classification system for each
clinical trial was reported as a footnote at the bottom of each adverse event table, the table for
serious events and the table for other (not including serious) events. Please see the screenshot
below in Figure 6 below. Therefore, manual data extraction of these data points was required.

The two data points, controlled terminology/classification system and adverse event data
collection methods, were entered into two newly created columned in the Excel spreadsheet for
analysis. In addition, the date of the first result entry and the date of last result update for each
clinical trial arm was recorded in two more discrete data columns within the spreadsheet. Pivot
tables were created to analyze clinical trial investigator choice of controlled
terminology/classification system for each term which representing a severe hypersensitivity
adverse event. Then, descriptive analysis was performed to determine the total number of
different terminology and classification system types used to describe these events. Also, the
total number of clinical trial participant adverse events and the total number of at-risk clinical
trial participants was determined for each adverse event term and terminology/classification
system in the severe hypersensitivity data subset.
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In cases where there were no superscript or footnotes, the clinical terminology and collection
method was recorded as “not specified”. Using the date of first recorded result, tables of
terminology/classification systems by initial year of use and date ranges of
terminology/classification system use was created. Additionally, the number and types of
versions of each system was determined.

Figure 6. Screen Shot of Clinical Trial Adverse Event Results with Controlled
Terminology Type and Collection Method
superscript

Footnote
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Part 4: Methods used to test each hypothesis

Hypothesis #1:
The ability to accurately document severity of hypersensitivity events secondary to cancer
biological or chemotherapy agents is improving with the use of the CTCAE classification system
and its emphasis on severity levels in comparison to MedDRA.

Test of presence of severity grade
To test the hypothesis that the CTCAE classification system has improved the ability of clinical
investigators to capture the severity of severe anaphylactic and anaphylactoid events in clinical
cancer trials in comparison to MedDRA, first the terms used to describe these events in both
systems were analyzed and categorized in to groups based on the type of terminology used to
describe the event and whether a grade level was included, for example CTCAE terms with a
grade, CTCAE with no grade, MedDRA terms with a grade, MedDRA terms with no grade,
terms with no specified terminology with a grade etc. MedDRA is expected to not include grade
levels, therefore, CTCAE should in theory, perform better in capturing hypersensitivity event
severity. Second, due to low cell levels of less than 5, a Fisher’s exact test was used to test the
statistical difference between categories. The category of cytokine release syndrome/infusion
reaction events was analyzed separately as these are categorized differently in CTCAE as
discussed in Chapter 2.
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Test of accuracy of hypersensitivity adverse event severity
The data subset of severe anaphylactic and anaphylactoid adverse events was categorized into
two subgroups: Serious events and other (not including serious) events. Anaphylactic and
anaphylactoid types events are by definition severe and as discussed in Chapter 2, the
classification system for CTCAE does not allow for coding of these events at grades lower than
three (severe). Therefore, adverse events reported by clinical trial investigators as “other (not
including serious)” have not accurately recorded the severity level of the anaphylactic or
anaphylactoid adverse event.

To test the hypothesis of whether the NCI CTCAE classification system with its emphasis on
severity grade levels (one through five) is improving the ability to accurately record
hypersensitivity event severity, the most common terms from the severe data subset were divided
into four subgroups: anaphylactic events labeled serious using the MedDRA term “anaphylactic
reaction”; anaphylactic events mislabeled as other using the MedDRA term “anaphylactic
reaction”; anaphylactic events labeled serious using the CTCAE term “anaphylaxis” or
“anaphylaxis to X” or “X anaphylaxis” where X is equivalent to the antigen; and anaphylactic
events mislabeled other using the CTCAE term “anaphylaxis”. Given both terms represent
severe events, neither term should be represented in the “other (not including serious)” adverse
event table. In other works, the value for adverse hypersensitivity events labeled with one of
these two terms should be labeled as serious and not labeled as other than serious as discussed in
Chapter 2. Please see Table 4 below.
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Table 3. Method for comparing accuracy of severity label for severe hypersensitivity
events
Term
Anaphylactic
Reaction

Serious Events

Other Events

Total

A

B

A+B

C

D

C+D

A+C

B+D

A+B+C+D

(MedDRA Term)
Anaphylaxis
(CTCAE Term)
Total

The percentage of severe events coded as “other (not including serious) was determined for each
term. Additionally, the statistically difference between the observed events in each category was
compared to the expected events in each category. The expected number in each category was
determined by multiplying the total number of events in the corresponding column by the
corresponding row and dividing the product by the total number of events. For example, in
Table 3, the expected number of serious anaphylactic events mislabeled as “other than serious”
using the MedDRA term “anaphylactic reaction” was determined by
(B+D)*(A+B)/(A+B+C+D). A Chi Square test was then used to determine if there was a
significant difference between the MedDRA terms, CTC terms, CTCAE terms, and Not
Specified terms groups. (Hall & Richardson, 2016)

Hypothesis #2:
Terms used to describe severe anaphylactic and anaphylactoid events recorded in the dataset of
clinical cancer trials from ClinicalTrials.gov rarely (<5% of events) include the antigen
responsible for the event which hinders the ability to study incidence of drug and biological
agent induced hypersensitivity events when the clinical trial intervention includes multiple drugs
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and/or multiple therapeutic agents. In other words, there is no statistical difference between the
types of terminologies or classification systems used regarding the inclusion of the antigen
within the severe hypersensitivity event term.

The subset of severe anaphylactic and anaphylactoid adverse events which included the terms
anaphylaxis, anaphylactic reaction, anaphylactic shock, and grade 3 or 4 allergic or
hypersensitivity reactions, and variations of these terms, e.g. “Bactrim anaphylaxis”, were
categorized into groups by the type of controlled vocabulary or classification system and whether
the term including the name of the allergen which was the etiology of the severe hypersensitivity
event. The categories were compared statistically with the Fisher’s exact test (due to cell
numbers less than 5) to determine if a statistical significance exists between the terminology,
classification system, or unspecified terminology groups with regards to the inclusion of the
allergen. The same method was used to analyze the cytokine release syndrome and infusion
reaction group.

Hypothesis #3: Over 25% of the severe anaphylactic and anaphylactoid events have not been
collected using a systematic assessment method which could result in underreporting of events.

Data regarding collection approach methods were reported as a footnote below the semistructured adverse event tables in ClinicalTrials.gov which required manual data extraction of
the descriptive terminology and data collection method. Please refer to Figure 5 above. The
unique NCI identification number of the trial arm was used to query the database via the search
engine found at the ClinicalTrial.gov home page. Adverse event collection methods were
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recorded in a separate column in the datasheet as either systematic assessment, non-systematic
assessment or unspecified collection method which are the only permissible values in the adverse
event tables, see Figure 4 above. The incidence of use of a systematic assessment collection
method was calculated for severe hypersensitivity adverse events using the most commonly
recorded terms: anaphylaxis, anaphylactic reaction, anaphylactic shock, and anaphylactoid
reaction. Each adverse event was categorized by term and collection method. A Chi Square test
was used to analyze if there was a significant difference between the terms used and the
collection method.
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Chapter IV. Results

Descriptive Analysis
The final dataset of adverse immune events included 1331 NCT unique clinical trial ID numbers
and 5595 clinical trials arms (each clinical trial may have more than one). The results of the
descriptive analysis of total immune system disorder events, in all clinical trials reporting
adverse events, returned 13,088 recorded adverse immune mediated events out of 895,383
participants at risk for an event after exposure to a clinical trial arm intervention. These results
indicate an overall incidence of 0.0146 or approximately 1.5% for adverse immune related
events in this clinical cancer trial dataset over the timeframe of September 1999-March 2018.

These 1331 clinical cancer trials involved 639 unique cancer condition combinations. Some of
the cancer conditions were included in more than one trial. For example, one trial investigated
interventions for B-cell lymphoma and follicular lymphoma while another trial investigated Bcell lymphoma in addition to several other types of lymphoma such a T-cell lymphoma. The
most commonly reported types of cancer in the clinical trials reporting immune disorder events
were breast cancer/neoplasms, multiple myeloma, colorectal cancer, lymphoma, leukemia and
non-small cell lung cancer. Some conditions were labeled only as “cancer”, “neoplasms”, “solid
tumor” or “carcinoma” which made analyzing the cancer type difficult.

The most frequently used term to describe immune disorder adverse events in clinical trial arms
was “hypersensitivity”. This high-level term was used in approximately 22.1% of clinical trial
arms, nearly one quarter. It also has the least ability to provide detail on allergen and severity.
The next most frequently used terms to describe these events were: allergic reaction (11.0%),
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drug hypersensitivity (10.3%), anaphylactic reaction (5.2%), cytokine release syndrome (4.1%),
allergic reaction/hypersensitivity (including drug fever) (3.6%), anaphylaxis (3.4%), seasonal
allergy (3.4%), anaphylactic shock (2.1%), allergic reaction/hypersensitivity (1.8%), and allergic
rhinitis (including sneezing, nasal stuffiness, postnasal drip) (1.9%). The other terms were each
mentioned in 65 or less clinical trial arms (1.2% or less). These results are visualized in Table 4
below.

Table 4. Hypersensitivity Term Frequency in Cancer Clinical Trial Arms

Lower level terms which indicated severity or included allergen descriptors were used far less
often. For example, the term “allergic reaction” can be used to record a hypersensitivity event,
however, when using the CTCAE classification system, the term should include a grade level. In
the 5595 clinical cancer trial arms, the terms which included a grade descriptor with the adverse
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hypersensitivity event were infrequent. Three clinical trial arms (0.05%) used the term “Grade 1
Allergic reaction/hypersensitivity”, three arms used the term “Grade 1” Allergic rhinitis, and five
arms used “Grade 3 Allergic reaction/hypersensitivity” (0.08%). Two clinical trial arms (0.04%)
used the term “hypersensitivity – grade 2”. Finally, two clinical trials arms used terms which
included grade 4 as a descriptor. A total of 40 clinical trial arms used a hypersensitivity or
immune disorder term with a grade level out of the total of 5595 arms in the dataset. The
calculated percentage of use in clinical trial arms was 0.7%.

Subset of Severe Anaphylactic and Anaphylactoid Events
A case study of severe adverse events, a subset of anaphylactic and anaphylactoid events, was
created. Events with the high-level term “autoimmune disorder” or “hypersensitivity” or
“allergic reaction” were not included as it was not possible to determine if these events were of
the anaphylactic or anaphylactoid type. Terms included in this data subset were: Anaphylaxis,
anaphylactic reactions, anaphylactoid reaction, allergic reaction – anaphylactic, and grade 3-5
allergic reactions. Table 6 below lists the severe hypersensitivity adverse event, the number of
affected clinical trial participants, the number of clinical trial participants at risk (exposed to the
intervention) and the number of clinical trial arms.
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Table 5. Immune Disorder Terms with Adverse Event Severity Grade
Adverse Immune Disorder Event
Autoimmune disorder - grade 1
Autoimmune disorder - grade 2
Autoimmune disorder - grade 3
Autoimmune disorder - grade 4
Gr3 Neturopenia
Grade 1 Allergic
reaction/hypersensitivity
Grade 1 Allergic rhinitis
Grade 1 Autoimmune reaction
Grade 1 Rhinitis
Grade 2 Allergic reaction
Grade 2 Allergic
reaction/hypersensitivity
Grade 2 Rhinitis
Grade 3 Allergic
reaction/hypersensitivity
Grade 3 Allergic/hypersensitivity
Grade 3 Autoimmune reaction
Grade 4 Allergic
reaction/Hypersensitivity
Grade 4 Allergy-other
Grade 4 Autoimmune reaction
Hypersensitivity - Grade 2
Hypersensitivity - Grade 3
Leukopenia (Grade 1)
Leukopenia (Grade 2)
Total

Count NCT Affected
At risk
ID
number
number
1
15
15
1
2
15
1
9
15
1
1
15
1
2
5
3
70
345

39

3
2
4
1
1

103
53
46
1
27

751
668
353
30
303

2
3

20
8

311
345

2
3
1

1
6
2

668
971
303

1
2
2
3
1
1
40

1
4
1
3
1
1
377

303
668
38
74
12
12
6220

Table 6. Anaphylactic and anaphylactoid Event Subset

Row Labels
allergic reaction - anaphylactic
Anaphylactic reaction
Anaphylactic Reaction to Anti-Thymocyte Globulin
Anaphylactic shock
Anaphylactoid reaction
Anaphylaxis
Anaphylaxtic reaction to erbitux
Angioedema
Bactrim anaphylaxis
Cryoglobulinaemia
Cytokine release syndrome
Cytokine Release Syndrome (Stem Cell Infusion)
Cytokine Release Syndrome (Thymoglobulin)
Cytokine release syndrome, ATG
Cytokine release syndrome/acute infusion reaction
Cytokine storm
Death
Grade 3 Allergic reaction/hypersensitivity
Grade 3 Allergic/hypersensitivity
Grade 4 Allergic reaction/Hypersensitivity
Grade 4 Allergy-other
Hypersensitivity - Grade 3
Grand Total

Sum of
affected_number
4
153
1
58
9
935
3
1
1
1
509
2
1
12
17
1
8
8
1
2
1
3

Sum of
at_risk_number
47
107488
57
41075
19814
29087
37
57
85
37
28793
6
6
17
711
207
66
345
668
303
303
74

1731

229283

Description of Terminology and Classification Systems in the case study subset
The clinical trial investigators reporting of initial years of clinical trial registration for studies
which used CTC were from 2000-2010. No new studies used this classification system after
2010. CTCv2.0 was initially used in 2000 and last used in an update in 2017. CTCv4.0 was
initially posted in 2003 and last used in an update in 2019. The next most common type used
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Count
of
NCT_id
1
290
2
116
26
193
1
1
2
2
230
2
2
1
27
1
2
3
2
1
1
3
909

was the MedDRA terminology, 28 different versions were used to record these events, however,
a MedDRA version was not listed in 39 of the anaphylactic data subset of events. The first time
MedDRA was used to report an event was in 2002 and the last time it was used in an update was
2020. The complete list of MedDRA dates by version is available in Appendix A.

CTCAE versions 2.0, 3.0 and 4.0 were used in 48 of the events beginning with year 2003
through last updates in 2019. By version for this data subset, CTCAE 2.0 was first used in 2003
and last used in an update in 2019; CTCAE 3.0 was first used in 2004 and last used in an update
in 2019; CTCAE 4.0 was first used in 2003 and last used in an update in 2019. In this data
subset of severe anaphylactic type reactions, CTCAE 5.0 was not used at all.

In the data subset of severe anaphylactic or anaphylactoid type hypersensitivity events which
totaled 1238 adverse events out of 199,155 exposures (incidence 0.0062), the most commonly
used terminology type was Common Toxicity Criteria (CTC). A 704 of the events (56.9%) were
recorded with this type of classification system.
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Table 7. Anaphylactic and Anaphylactoid Event Terminology or Classification Systems

No. Severe Anaphylactic Events

704

216

204

113
1
CTCAE

CTC

MedDRA

Not specified

COSTART,
CTCAE v3.0

Terminology System Used

Severity data element
The ClinicalTrial.gov requires the investigator to enter the adverse events into one of two
possible adverse event tables, serious or other (not including serious). The adverse immune
disorder events returned from a query of the dataset was divided into these two groups as
follows: 2,409 participants experiencing a “serious” immune disorder event and 10,679
participants experiencing an “other (not including serious)” event. Taking the number of
participants affected by an event in context with the number of clinical trial participants at risk
for an event, less than 1% of clinical trial participants experienced a serious immune disorder
event and approximately 1.7% experienced an “other (not including serious)” immune disorder
event.
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Table 8. Adverse Immune Events in Clinical Cancer Trials (1999-2018)

Adverse
Immune
Events

Participants
Affected

Participants
as Risk

% Affected

Serious
events

2409

251399

0.0096

Other
events

10679

643984

0.0166

From a clinical trial arm perspective, each clinical investigator selected terms to describe the
immune disorder adverse events which occurred in the clinical trial arms. Each clinical trial arm
represented a different type of clinical cancer intervention for an NCI trial identification number.
Therefore, each clinical trial could report an adverse event incidence for multiple arms in each of
the adverse event tables (severe or other than serious). Additionally, a clinical trial could report
“0” events for a particular event in a clinical trial arm.

Cytokine Release Syndrome (CRS)
A total of 542 cytokine release syndrome type adverse immune disorder events were reported in
this dataset. The terms used to report this type of immune related event were: Cytokine release
syndrome, cytokine release syndrome (stem cell infusion), cytokine release syndrome
(thymoglobulin), cytokine release syndrome, ATG, cytokine release syndrome/acute infusion
reaction, and cytokine storm. The majority of these events (85%) were recorded as other than
serious events. However, none of the reactions included a grade level. Although, minimal use of
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CTCAE version 4 and no use of CTCAE version 5 (published 2017) (U.S. Department of Health
and Human Services, 2017) was recorded and the grade levels for this condition first appeared in
version 4.0. Figure 7 below visualizes the percentage of CRS adverse events which were labeled
as serious verses other events.

Figure 7. Cytokine Release Syndrome (CRS) Adverse Event Severity

CRS Events

15%
Other events
Serious events

85%

Hypothesis #1
The ability to accurately document severity of anaphylactic and anaphylactoid events secondary
to cancer biological or chemotherapy agents is improving with the use of the CTCAE
classification system and its emphasis on severity grade levels (1-5) in comparison to MedDRA.
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The results indicate this hypothesis is not true. When CTCAE terminology was used to describe
severe anaphylactic or anaphylactoid events, the CTCAE grading system was not used. In
addition, the severity of the preferred term in the CTCAE classification system to describe
anaphylactic events, “anaphylaxis”, was often miscoded as “other (not including serious)”
instead of “serious” in the data field which allows one of these two permissible values which
corresponds to the particular adverse event table (serious or other).

Severity Grading of Anaphylactic or Anaphylactoid Events
ClinicalTrials.gov does not have a severity grading data field, instead the NCI encourages
clinical trial investigators to report adverse clinical cancer trial events using the CTCAE
classification system, which uses clinical symptoms and signs as criteria to determine the adverse
event severity grades levels one through five as discussed in Chapter 2. The grade is then
included with the term, for example, Grade 4 Anaphylaxis. (Unified Medical Language System,
n.d.) The 48 severe anaphylactic and anaphylactoid adverse events reported using the CTCAE
classification system, including versions CTCAE 2.0, CTCAE 3.0, or CTCAE 4.0, did not
include a severity grade levels in any of the event terms. CTC, the older version of CTCAE, also
did not include severity grade levels in any of the 704 reported events using this classification
system. MedDRA did include a grade level in one of the 216 events reported using this
terminology system. Only six clinical trial arms were not able to be categorized into the above
groups: “Adeers not subm” (1); “COSTART, CTCAE v3.0” (1); “15” (1); “17” (3). It is likely
“15” and “17” refer to MedDRA versions, however, this cannot be certain so these were
removed from the analysis.
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Table 9. Terminology or Classification System and Event Severity Grading
Terminology or Classification System
CTC
MedDRA
CTCAE
Not Specified
Total

No Grade
704
215
48
190
1157

Grade
0
1
0
14
15

Total
704
216
48
204
1172

Severe allergic anaphylactic type events reported with a “not specified” terminology of choice
did include grade levels in fourteen clinical trial arms as noted in the table above. The
investigators in these cancer clinical trials used the terms “Grade 3 Allergic/hypersensitivity”,
“Grade 3 Allergic reaction/hypersensitivity”, “Grade 4 Allergic reaction/Hypersensitivity” and
“Grade 4 Allergy-other”. Although, the type of vocabulary or classification system for these
terms were not specified, according to the UMLS, the terms are similar to the CTCAE version
3.0 term “Grade 3 Allergic Reaction and Hypersensitivity Including Drug Fever, CTCAE
[A29146280/NCI_CTCAE_3/PT/C54752]” and “Grade 4 Allergic Reaction and Hypersensitivity
Including Drug Fever, CTCAE [A29160643/NCI_CTCAE_3/PT/C54757]” (Unified Medical
Language System, n.d.)

A Fisher’s Exact Test was used to test the statistical difference due to category totals < 5.
Interestingly, the clinical trials which did not specify their terminology or classification system
of choice were significantly more likely to include the grade level in comparison to the MedDRA
terminology described events with grades levels (Fisher exact test statistic = 0.0003, p < 0.05).
This also held true for the comparison between the “not specified” terminology events and the
CTC classification system term events with grade levels (Fisher exact test statistic value
<0.00001, p < 0.05). There was no statistical different between the CTCAE classification system
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and the “not specified” terminology events, (Fisher exact test statistic value = 0.0786, p < 0.05),
however, it may have been secondary to a lower number of events in the CTCAE category.

Table 10. Terminology Grading
Term
CTC
MedDRA
CTCAE
Not Specified
Totals

No Grade
704
215
48
190
1157

Grade
0
1
0
14
15

Totals
704
216
48
204
1172

No Grade
215
48
263

Grade
1
0
1

Marginal Row Totals
216
48
264(Grand Total)

Fisher's Exact Tests
MedDRA
CTCAE
Marginal Column Totals

The Fisher exact test statistic value is 1. The result is not significant at p < .05.

CTCAE
Not Specified
Marginal Column Totals

No Grade
48
190
238

Grade
0
14
14

Marginal Row Totals
48
204
252 (Grand Total)

The Fisher exact test statistic value is 0.0786. The result is not significant at p < .05.

CTC
CTCAE
Marginal Column Totals

No Grade
704
48
752

Grade
0
0
0

Marginal Row Totals
704
48
752(Grand Total)

The Fisher exact test statistic value is 1. The result is not significant at p < .05.

MedDRA
Not Specified
Marginal Column Totals

No Grade
215
190
405
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Grade
1
14
15

Marginal Row Totals
216
204
420(Grand Total)

The Fisher exact test statistic value is 0.0003. The result is significant at p < .05.

CTC
Not Specified
Marginal Column Totals

No Grade
704
190
894

Grade
0
14
14

Marginal Row Totals
704
204
908 (Grand Total)

The Fisher exact test statistic value is < 0.00001. The result is significant at p < .05.

(Stangroom, 2020)

Accuracy
Additionally, the CTCAE preferred term for anaphylactic events, “anaphylaxis”, was miscoded
as an “other (not including serious)” event the majority of the time in the ClinicalTrials.gov
dataset. “Anaphylaxis” was only labeled correctly as a severe event 222/935 (23.7%) of the
time. This term was coded in the dataset using CTCAE in the majority of these events, that is
the investigator indicated their controlled terminology or classification system of choice as being
CTCAE versions 2.0, version 3.0, or version 4.0. In contrast, the use of the MedDRA term
“anaphylactic reaction” was miscoded far less as an “other (not including serious)” event. This
reporting error occurred in only 5% of its use in this dataset as shown in Table 11 below.
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Table 11. Anaphylactic Terms Miscoded as Other (Not including Serious)

800
600
400
200
0
Other Label
Severe Label

Severe Label

Other Label

Using a chi square test, the proportion of investigator correct identification of the MedDRA term
“anaphylactic reaction” as a severe immune disorder adverse event was compared with the
proportion of investigator correct identification of the CTCAE term “anaphylaxis” as a severe
immune disorder adverse event. The results indicate that there is a significant difference in the
correct identification of an anaphylactic event as severe when using the MedDRA term
“Anaphylactic reaction” (92.3% correct) in comparison to using the CTCAE term “Anaphylaxis”
(23.8% correct, p-value < 0.001). See the Table 12 below for the category counts and chi square
value.
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Table 12. Comparison of Accuracy of Severity by Term Use
Term
Anaphylactic reaction
Anaphylaxis
Total

Severe
145
223
368

Other

Total
12
713
725

P-Value

157
936
1093 1.8939E-63

Cytokine Release Syndrome (CRS) Severity Reporting
The severity of CRS events was coded using the permissible values, serious or other (not
including serious). CRS is a variable condition, therefore, CTCAE does allow grading at all five
levels. Therefore, it was not possible to determine if the event was correctly coded or not as a
serious event without having direct access to the original data. Table 13 below lists the adverse
event terms and the proportion of severe and not severe events per term used to describe these
adverse events.

As noted above in the descriptive analysis, no severity grading levels were reported with the
terms used to describe cytokine release syndrome or acute infusion reactions. Although, the
CTCAE classification has terms available to describe severity grades by symptom criteria and
oxygen requirements, for example “Grade 3 Cytokine Release Syndrome [C4686146]”. (Unified
Medical Language System, n.d.)
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Table 13. Cytokine Release Syndrome Event Severity
Term
Cytokine release syndrome
Cytokine release syndrome (Stem Cell Infusion)
Cytokine release syndrome (Thymoglobulin)
Cytokine release syndrome, ATG
Cytokine release syndrome/acute infusion
reaction
Cytokine storm
Total

Serious
78
0
0
0
4

Other
431
2
1
12
13

Total
509
2
1
12
17

1
83

0
459

1
542

Hypothesis #2
Severe anaphylactic and anaphylactoid events recorded in ClinicalTrials.gov rarely (<5% of
events) include the allergen responsible for the event which hinders the ability to study incidence
when multiple drug or multiple therapeutic agents are used in clinical cancer trials. In other
words, there is no statistical difference between the most common terminologies used in this
database regarding the inclusion of the drug allergen in the allergic event term.

This hypothesis is true when analyzing the events which included the terminology or
classification system name. As expected, the most commonly used terminologies and
classification systems by the investigators did not support the inclusion of a drug or biological
allergen. MedDRA, CTC and CTCAE did not have the ability to capture the allergen
responsible for the event. Only two other systems were noted Adeers and COSTART which
were used in one arm each and also did not note allergens within the terms. The majority of
severe anaphylactic and anaphylactoid events were recorded by clinical investigators using CTC
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and all of the 704 events reported with this classification system used the term was
“anaphylaxis”.

Additionally, in this subset of severe events, several of the clinical trial investigators did not
specify the terminology or classification system used. However, a few of the events in this “not
specified” category included the allergen responsible for the severe allergic event (5/204). In
other words, the only allergens recorded in any of the severe anaphylactic and anaphylactoid
events were the adverse events in which the terminology or classification system was not
specified by the clinical investigator. For example, “Bactrim anaphylaxis” was used to describe
an anaphylactic event. The only other terms noted to have the allergen included were
“anaphylactic reaction to Erbitux” and “anaphylactic reaction to anti-thymocyte globulin”, as
shown in Table 14 below.

Table 14. Inclusion of Allergen with Anaphylactic and Anaphylactoid Events
Terminology or Classification System
CTCAE
CTC
MedDRA
Unspecified

Allergen
0
0
0
5

No Allergen
48
704
216
199

Total
48
704
216
204

Table 15. Fisher’s Exact Tests Comparing Allergen Inclusion
Results
Allergen

No Allergen

Marginal Row Totals

CTCAE

0

48

48

CTC

0

704

704

Marginal Column Totals

0

752

52

752 (Grand Total)

Fisher exact test statistic value = 1. The result is not significant at p < .05.
Results
Allergen

No Allergen

Marginal Row Totals

CTCAE

0

48

48

MedDRA

0

216

216

Marginal Column Totals

0

264

264 (Grand Total)

Fisher exact test statistic value = 1. The result is not significant at p < .05.
Results
Allergen

No Allergen

Marginal Row Totals

CTCAE

0

48

48

Unspecified

5

199

204

Marginal Column Totals

5

247

252 (Grand Total)

The Fisher exact test statistic value = 0.5867. The result is not significant at p < .05.
Results
Allergen

No Allergen

Marginal Row Totals

MedDRA

0

216

216

Unspecified

5

199

204

Marginal Column Totals

5

415

420 (Grand Total)

The Fisher exact test statistic value = 0.0264. The result is significant at p < .05.
Allergen

No Allergen

Marginal Row Totals

MedDRA

0

216

216

CTC

0

704

704

Marginal Column Totals

0

920

920 (Grand Total)

The Fisher exact test statistic value = 1. The result is not significant at p < .05.
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Allergen

No Allergen

Marginal Row Totals

CTC

0

704

704

Not Specified

5

199

204

Marginal Column Totals

5

903

908 (Grand Total)

The Fisher exact test statistic value = 0.0006. The result is significant at p < .05.

Table 16. Cytokine Release Syndrome Terms and Severity
Term
Cytokine release syndrome
Cytokine release syndrome (Stem Cell Infusion)
Cytokine release syndrome (Thymoglobulin)
Cytokine release syndrome, ATG
Cytokine release syndrome/acute infusion reaction
Cytokine storm
Total

Serious
78
0
0
0
4
1
83

Other
431
2
1
12
13
0
459

Total
509
2
1
12
17
1
542

Although, there seems to be a trend noting the lack of notation of an allergen with CRS severe
events in comparison to CRS other than serious events, the statistical comparison using a
Fisher’s exact test between the categories was not significant (p < 0.05).

Table 17. Cytokine Release Syndrome Event Allergen Inclusion and Severity
Allergen
Included
0

No Allergen
Included
83

Total

CRS Other Events

15

431

446

Total

15

514

529

CRS Serious Events

(Stangroom, 2020)

54

Fisher exact test
value

83
0.1442

Hypothesis #3
Over 25% of the severe allergic events have not been recorded using a systematic assessment
method which could result in underreporting of events.

The hypothesis was found to be true as only 18% of the subset of severe anaphylactic and
anaphylactoid events were collected using a systematic collection method. However, this
hypothesis is difficult to assess completely due to the large number of adverse events in the
severe anaphylactic or anaphylactoid data subset labeled as “not specified” in the collection
method data field. Over 75% of the events were collected with a “not specified” method, 18%
were collected using a systematic assessment method and 6% were collected using a nonsystematic collection method as noted in the pie graph in Figure 8 below.

Figure 8. Collection Method of Anaphylactic and Anaphylactoid Events

Collection Method

18%
6%
76%

Systematic Assessment Method

Non-Systematic Assessment Method

Not Specified
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However, the collection methods varied by terminology or classification system. In this data
subset, 877/937 (93.6%) events including the term “anaphylaxis” (primarily used with CTC and
CTCAE classification systems) were collected using an unspecified collection method. In
contrast, only 6/157 (3.8%) of terms labeled as “anaphylactic reaction”, primarily a MedDRA
terminology term, were collected with an unspecified collection method. In fact, 107/157
(68.2%) of events labeled using the term “anaphylactic reaction” were collected using a
systematic assessment method. However, 44/157 (28%) of the “anaphylactic reaction” events
were collected with a non-systematic assessment method. This remains consistent with the
hypothesis that over 25% would be collected using a non-systematic method. Tables 17
visualizes the terms and their collection methods. Table 18 below lists the exact numbers by
term and collection assessment method.

Table 18. Visualization of Anaphylactic and Anaphylactoid Term Collection Methods
877
900
800
700
600
500
400
300
200
100

107
44

43 14

6

1

55

7

5

2

0

0
Anaphylactic
reaction

Anaphylactic
shock

Systematic Assessment

Anaphylaxis

Non-Systematic Assessment

56

Anaphylactoid
reaction
Not Specified

Table 19. Severe Anaphylactic Type Adverse Events by Collection Methods Categories

Anaphylactic reaction
Anaphylactic shock
Anaphylaxis
Anaphylactoid reaction
Total

Systematic
Assessment
107
43
55
7
212

Non-Systematic
Assessment
44
14
5
2
65

Not Specified

Total

6
1
877
0
884

157
58
937
9
1161

A Chi Square test was used to analyze if there is a significant difference between the categories
of collection method (systematic assessment, non-systematic assessment or not specified) and
investigator selected term of choice. There was a significant difference in assessment methods
when all categories were tested, including not specified was tested (p value < 0.05) shown in
Table 19 below. When just testing for a significant difference between the terms and
assessment method categories without the “unspecified” category, the p value remained
significant at 0.0012 shown in Table 20 below.

Table 20. Chi Square Test of Collection Method and Term Categories

Chi Square
Observed
Anaphylactic reaction
Anaphylactic shock
Anaphylaxis
Anaphylactoid
reaction
Total
P-value

Systematic
Assessment
107
43
55
7

Non-Systematic
Assessment
44
14
5
2

Not Specified

Total

6
1
877
0

157
58
937
9

212
1.4816E-175

65

884

1161
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Expected
Anaphylactic reaction
Anaphylactic shock
Anaphylaxis
Anaphylactoid
reaction
Total

Systematic
Assessment
28.66838932
10.59086994
171.0973299
1.643410853

Non-Systematic
Assessment
8.789836348
3.247200689
52.45908699
0.503875969

Not Specified

Total

119.5417743
44.16192937
713.4435831
6.852713178

157
58
937
9

212

65

884

1161

Table 21. Chi Square Test of Collection Method and Terminology Categories without
Unspecified Values

Chi Square Without Not Specified Category
Systematic
Observed
Anaphylactic
reaction
Anaphylactic shock
Anaphylaxis
Anaphylactoid
reaction
Totals
P-value
Expected
Anaphylactic
reaction
Anaphylactic shock
Anaphylaxis
Anaphylactoid
reaction
Total

Totals

Assessment
107

Non-Systematic
Assessment
44

43
55
7

14
5
2

57
60
9

212
0.001222425

65

277

151

Systematic
Assessment
115.566787

Non-Systematic Assessment
35.433213

151

43.62454874
45.92057762
6.888086643

13.37545126
14.07942238
9

57
60
9

212

65

277

58

Figure 9 uses a pie graph to visualize the large number of anaphylactic and anaphylactoid events
in which the clinical investigator did not specify their collection method as either systematic or
non-systematic. Figure 10 displays the information in a pie graph using only the specified
collection methods.
Figure 9. Pie Graph Displaying Anaphylactic and Anaphylactoid Adverse Event Collection
Methods
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Figure 10. Pie Graph Displaying Anaphylactic and Anaphylactoid Adverse Event
Collection Method without Not Specified Category
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Chapter V. Discussion

Cancer clinical trials involve complex treatment interventions and often these interventions
involve a combination of both biologic therapies (monoclonal antibodies) and chemotherapies.
Monitoring adverse events involving new cancer therapies is important for patient safety
especially potentially life-threatening hypersensitivity reactions. Population level research can
aid in providing frontline health providers such as physicians, nurses, and physician assistants
with knowledge of potential predictors and risk factors for severe hypersensitivity reactions
which can improve clinical cancer therapy and provide at-risk patients with screening and
desensitization therapies if necessary to maintain first line therapies for cancer treatment.
Furthermore, population level research can increase the power of studies of rare disease with
meta-analysis methods. The adverse hypersensitivity event data from these trials can improve
emergency preparedness for life-threatening infusion reactions (cytokine release syndrome),
anaphylactic or anaphylactoid reactions. Unfortunately, the current process for collecting and
recording the characteristics of these types of events is fault with poor granularity, inaccuracies
in severity, missing information, controlled terminology challenges and inconsistent collection
methods.

The findings of this study indicate that several gaps exist in reporting of cancer clinical trial
hypersensitivity events, especially severe anaphylactic and anaphylactoid events. The specific
areas of concern in clinical trial severe hypersensitivity event reporting were the accuracy of
reporting the hypersensitivity event severity when using the CTCAE preferred term
“anaphylaxis”, the lack of investigator use of the CTCAE severity grading system, and the lack
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of ability to capture the drug allergen responsible for the severe anaphylactic, anaphylactoid or
CRS related adverse events in multi-drug therapies. Furthermore, a large portion of clinical
cancer trials either did not report their adverse event collection method or do not use a systematic
assessment method of collecting these adverse events which could lead to under reporting of
these events.

Granularity
An overall analysis of the terms used in clinical trial reporting of immune disorder adverse
events indicates the most common term used to describe cancer immune disorder adverse events
was “hypersensitivity”. This term was used to describe 22.2% of the immune adverse events
over the nine year study period in which the data in this dataset was entered into
ClinicalTrials.gov. Hypersensitivity is a high-level term which lacks necessary descriptors to
perform adequate pharmacovigilance of drug or biological agent monitoring of immune disorder
events during clinical trials. The term does indicate the event severity or whether the event was
allergic or non-IgE in pathophysiology. Furthermore, this term does indicate the etiology or
allergen responsible for the hypersensitivity event occurring while the patient is receiving a
clinical trial intervention which often involve multiple drugs, biological agents and/or other
therapies such as radiation and surgery. In other words, without any further information, this
term alone will not aid in surveillance of drug or biological agent adverse hypersensitivity events
in clinical cancer trials. It may be the information which may have existed in the original
investigator data has not been adequately transferred to the ClinicalTrials.gov database and
therefore, not available to health consumers who may be searching for a potential clinical trial to
participate in.

61

Hypothesis #1
The ability to accurately document severity of anaphylactic and anaphylactoid events secondary
to cancer biological or chemotherapy agents is improving with the use of the CTCAE
classification system and its emphasis on grade levels (1-5) in comparison to MedDRA.

The results of the data analysis for hypothesis one indicates the use of the NCI CTCAE
classification system has not improved the ability to capture severity and has resulted in further
challenges in reporting severity level accuracy of anaphylactic events in clinical cancer trials.
This is indicated by the lack of clinical investigator use of the classification system’s grades to
capture the severity of these types of adverse events even with these terms available in the
CTCAE versions used in these clinical trials. In summary, clinical cancer trial investigators used
CTCAE terms which did not include the severity grading levels to describe these severe
anaphylactic and anaphylactoid adverse events. For example, an investigator may report
“Anaphylaxis, CTCAE [A29138945]” instead of “Grade 4 Anaphylaxis [A29149366]”.
(National Cancer Institute, n.d.)

Furthermore, the results indicate that the use of the most common term in this classification
system to describe severe anaphylactic events, “anaphylaxis”, has resulted in significantly more
errors in mislabeling anaphylactic events as “other (not including serious)” events in comparison
to the MedDRA classification system’s most common term to describe these events,
“anaphylactic reaction”. As discussed in Chapter 2, the CTCAE classification system grading
severity levels only allow for the grading of “anaphylaxis” at grade levels three (severe), four
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(life-threatening) and five (death). Therefore, these events should only be included in the severe
event table in ClinicalTrails.gov. However, this was not the case as the results indicate there
were significantly more CTCAE “anaphylaxis” events entered into the “other (not including
serious)” table in comparison to the MedDRA terminology equivalent term “anaphylactic
reaction” which was rarely mislabeled. The possibility exists that the definition of the term
“anaphylaxis” is not as well understood by clinical investigators in comparison to the MedDRA
term. Another possibility is the clinical investigators are labeling the severe grade 3 events
which are described in the CTCAE version 4.0 Quick Reference as “severe or medically
significant but not immediately life-threatening” as other than serious events due to the existence
of only two permissible severity levels (severe or other) in this database. (U.S. Department of
Health and Human Services, 2008)

The lack of use of severity grading levels and the incorrect labeling of these events will impact
the ability of public health and clinical research informatics investigators to study these severe
events on a population level across clinical trials. First and foremost, the ClinicalTrials.gov data
will not be able to distinguish which clinical trial participants developed adverse hypersensitivity
reactions which required immediate intervention for potentially life-threatening situations and
study potential predictors for these events. Secondly, the adverse events which resulted in death
may not be captured correctly by the data without the level 5 designation which directly
associates the hypersensitivity reaction with the adverse event. Finally, if the population level
researcher used only the severe adverse event table to study these severe events, the investigator
would inadvertently not capture a large number of mislabeled events in the “other (not including
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serious) table. This would result in a much lower incidence rate of severe anaphylactic events
secondary to clinical cancer trial drug and biological interventions.

Hypothesis #2
Severe allergic events recorded in ClinicalTrials.gov rarely (<5% of events) include the allergen
responsible for the event which hinders the ability to study incidence when multiple drug or
multiple therapeutic agents are used in clinical cancer trials. In other words, there is no
statistical difference between the most common terminologies used in this database regarding
the inclusion of the drug allergen in the allergic event term.

The first part of this hypothesis is true. All terminology and classification systems, in addition to
the events in which the terminology or classification system was not specified, rarely reported
the allergen responsible for adverse event. This was expected due to the terminology and
classification systems used in capturing the severe anaphylactic and anaphylactoid events. CTC,
CTCAE, and MedDRA did not have the ability to code the event and the drug or biological agent
responsible for the event. However, in studying the adverse event table arms, there was not an
ability to link the particular hypersensitivity event to a single drug in the multi-drug intervention
arms. For example, in Clinical Trial NCT00036738 which studies drug and radiation
interventions for leukemia, the single arm trial treatment is listed as including the following:
Arm/Group Title Treatment (Allogeneic Nonmyeloablative HSCT)
Arm/Group Description:
-Cyclosporine: Given IV or PO
-Dasatinib: Given PO
-Fludarabine Phosphate: Given IV
-Imatinib Mesylate: Given PO
-Mycophenolate Mofetil: Given PO
-Nilotinib: Given PO
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-Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo
nonmyeloablative allogeneic PBSC transplantation
-Peripheral Blood Stem Cell Transplantation: Undergo allogeneic PBSC transplantation
-Therapeutic Allogeneic Lymphocytes: Given IV
-Total-Body Irradiation: Undergo TBI (U.S. National Library of Medicine, 2020)

In this trial, one anaphylaxis event was record in the “Other (Not Including Serious) Adverse
Events Table”, however, the treatment interventions for this arm in the table was only listed as
“Allogenic Nonmyeloablative HSCT”. Therefore, it was not possible to determine which
intervention was the etiology of this event. Generally, with severe hypersensitivity events,
especially anaphylactic type events, there will be a close time association between the
administration of the drug or agent and the event. Therefore, without the ability to record or
effectively link the drug or agent intervention to the event, this information will be lost in the
transfer of the clinical trial data from the clinical investigator to the NLM ClinicalTrials.gov
database. The use of a terminology system such as RxNorm, which can capture the drugs in
relation to the events could be helpful. Furthermore, the use of a term which has the ability to
enter in a specific drug or biological agent with the event, such as the recent guidance for
collection of adverse infection events related to COVID-19. On March 25, 2020, the Department
of Health & Human Services Memorandum advised clinical investigators to use the term
“Infections and infestations – Other, specify; specify = COVID-19”. (Mooney, Moscow, Ivy, &
McCaskill-Stevens, 2020) A similar approach could be used to capture the drug etiology or
biological agent associated with the hypersensitivity event in clinical cancer trials. For example,
an additional field could be added for the immune category which requires the clinical
investigator to specify which drug or agent was related or the likely etiology of the
hypersensitivity event. Interestingly in NCT00040485, a similar terminology method was used
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to record a blood infection, “Infections and Infestations -Other (Blood). (U.S. National Library
of Medicine, 2020)

Regarding the second part of the hypothesis, there was no statistical difference between CTCAE,
CTC and MedDRA with regards to inclusion of allergen discriptors within the adverse event
term, however, there was a small statistical significant difference between the severe
anaphylactic terms recorded using MedDRA terminology and those terms recorded with an
unspecified terminology. Statistical significance was also found between the categories of
anaphylactic terms recorded using the CTC classification which included an allergen in
comparison to the terms recorded using an unspecified terminology which included the allergen.
This significance may be due to the increase in flexibility of clinical investigators entering free
text within the adverse event tables. For example, the term “Bactrim Anaphylaxis” was used
which in not in the UMLS system, however, easily identified the cause of the anaphylactic
reaction, the antibiotic sulfa drug, Bactrim.

Hypothesis #3
Over 25% of the severe allergic events have not been recorded using a systematic assessment
method which could result in underreporting of events.

The final hypothesis 3 was true, however, a large number of the clinical trials did not indicate
their method of collecting adverse events. In fact, a striking number of these trials, 76%, did not
report their method of assessment. Of the remaining 24% of clinical trials which did report
collection methods for severe anaphylactic and anaphylactoid events, approximately 75%
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collected their adverse events using a systematic assessment method. Therefore, if you remove
the unspecified category, the rate of systematic assessment collection method for cancer clinical
trial severe anaphylactic and anaphylactoid adverse events was equal to 25%.

The events recorded using the term “anaphylaxis” did not report their adverse event collection
method for immune disorders in 93.6% of the cases, the overwhelming majority of cases. This
was in contrast to the MedDRA terminology reported events which used a systematic assessment
collection method in the majority of cases (68.2%). Therefore, investigators using MedDRA
terminology were significantly more likely to report the use of a systematic method of
assessment for adverse events, however, it is difficult to determine which terminology or
classification system is more likely to use a systematic method given the large number of
unspecified method type data points for events coded using the CTCAE and CTC classification
systems.

The impact of using a non-systematic collection method for adverse event reporting is the
potential for not capturing events. In a non-systematic assessment collection method, adverse
immune events were not solicited by the clinical investigators and therefore, the events may or
may not be reported by the clinical trial participant. In a systematic assessment approach, the
clinical investigators use a protocol or pre-determined method to periodically assess for potential
adverse events such as a questionnaire or a diary. (National Institute of Health, 2020) Therefore,
without a protocol, even emergency room visits may be forgotten and not reported during the
regularly scheduled clinical trial visits. Under reporting of severe hypersensitivity events could
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lead to inaccurately high drug safety assessments. Therefore, the importance of rigorous adverse
event collection methods of severe events cannot be overstated.

Study Limitations
As discussed above, a significant limitation of the study is the high number of severe
anaphylactic events which were recorded using an unspecified terminology or classification
system.
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Chapter VI. Conclusion

The NCI CTCAE classification system was not found to improve the capture of severe
hypersensitivity events in the case study of anaphylaxis and anaphylactoid events. Lack of
clinical investigator adoption of CTCAE terms with grades contributed to the inability to capture
the severity level of anaphylactic or anaphylactoid events and resulted in no improvement in
comparison to the previous use of CTC and MedDRA systems. Furthermore, the CTCAE use of
the term “anaphylaxis” resulted in a significant increase in miscoding of this adverse event
severity level in comparison to the MedDRA equivalent term. Furthermore, the lack of
identification of the allergen etiology through the use of a term descriptor for these events in
multi drug or multi interventional trials continues to be a significant problem which hinders the
ability to use this data on a populations level for pharmacovigilance. The overwhelming
majoring of allergic reaction terms did not include the allergen and therefore, in dual or
multi- drug therapies, the etiologic agent was not identifiable.

To address these barriers to population level research of severe hypersensitivity events in clinical
cancer trials, further research should be done to analyze the reason for lack of investigator
adoption of the NCI CTCAE severity grade levels in severe hypersensitivity events.
Furthermore, a return to the use of the MedDRA term “anaphylactic reaction” should be
considered to avoid severity level confusion as this could make a significant impact on capturing
severity events in research. Also, further study and updating of CTCAE terms with a high
percentage of miscoding of severity levels should be considered. Furthermore, adapting terms
which include the drug or at least the drug class could significantly improve the ability to capture
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hypersensitivity event etiology. This could advance the quality of data in population level study
of anaphylaxis etiology and incidence in multi-drug cancer therapy, therefore, making a
significant impact on the safety of these drugs. Finally, systematic assessment adverse event
collection methods should be used in clinical trials to reduce the possibility of underreporting of
adverse hypersensitivity events.
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Appendix A: Cancer Drug and Biological Intervention Terms List
Intervention

Drug Class

Alternative names

Abbreviatio
n

Code name

cyclophosphamide

alkylatingAgent

Ciclofosfamida,Ciclofosfamida,
Ciclofosfamide,
Clafen,
Claphene,
CP monohydrate,
Cyclophospham,
Cyclophosphamid monohydrate,
Cyclophosphamidum,
Cyclophosphan,
Cyclophosphanum,
Cytophosphane,
Genoxal,
Syklofosfamid

CTX

WR-138719

etoposide

plantAlkaloid

Demethyl Epipodophyllotoxin Ethylidine
Glucoside epipodophyllotoxin

EPEG

VP-16, VP-16213

cytarabine

antimetabolite

cetuximab

monoclonalAB

vincristine sulfate

plantAlkaloid

vincristine sulfate
liposome
dexamethasone

plantAlkaloid

methotrexate

antimetabolite

.beta.-Cytosine arabinoside,
ARA-C
CHX-3311,
arabinofuranosylcytosine,
U 19920,
arabinosylcytosine, aracytidine, betaU-19920,
cytosine arabinoside, cytarabine
U-29920A HCl,
hydrochloride, cytarabinum, cytosine
WR-28453
arabinoside, cytosine arabinosine
hydrochloride,cytosine-.beta.-arabinoside,
Tarabine PFS
Anti-EGFR Monoclonal Antibody,
Chimeric MoAb
C225, IMC-C225
Anti-Epidermal Growth Factor Receptor
C225, MOAB
Monoclonal Antibody,
C225
C225 monoclonal antibody,
Chimeric Anti-EGFR Monoclonal Antibody,
Chimeric Monoclonal Antibody C225,
anti-(human epidermal growth factor
receptor) (human-mouse monoclonal C225
gamma1-chain), disulfide with humanmouse monoclonal C225 kappa-chain, dimer
monoclonal antibody C225, Erbitux
leurocristine sulfate, vincristine sulfate,
VCR
Vincosid, Vincasar PFS
liposomal vincristine sulfate, vincristine liposomal, vincristine sulfate liposome
injection, marqibo
Desamethasone, Dexamethasonum,
DM
disaimisong, DXM, Hexadecadrol, Maxidex,
Methylfluorprednisolone
CL-14377, WRalpha-methopterin,
MTX
19039
amethopterin,
methotrexate methylaminopterin,
Methotrexatum,
methylaminopterin,
Metotrexato

steroid
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prednisone

steroid

delta 1-cortisone,
Delta(1)-Cortisone,
deltacortisone,
deltadehydrocortisone,
metacortandracin,
PRD,
Prednisonum

PRED

doxorubicin

anthracycline

doxorubicin hydrochloride, ADR,
adriamycin,
adriamycin hydrochloride,
Adriamycine,
chloridrato de doxorrubicina,
doxorubicin.HCl,
hydroxydaunorubicin

ADM, Adria,
DOX

FI-106

fludarabine

antimetabolite

2-F-ara-AMP

SH T 586

cisplatin

platinum

fludarabine phosphate, fludarabine
monophosphate
CACP,
cis-DDP,
cis-diamminedichloridoplatinum,
cis-diamminedichloro platinum (II),
cis-diamminedichloroplatinum,
Cis-dichloroammine Platinum (II),
Cismaplat,
Cisplatina,
cis-platinous diamine dichloride,
cis-platinum,
cis-platinum II,
cis-platinum II diamine dichloride,
CPDD,
Cysplatyna,
DDP,
PDD,
Peyrone's Chloride,
Peyrone's Salt,
Platinoxan,
platinum diamminodichloride, Platinol,
Platinol-AQ

paclitaxel
liposomal paclitaxel

taxane
taxane

TAX
PNU-93914

rituximab

monoclonalAB

Taxol
LEP, liposome-encapsulated paclitaxel,
paclitaxel liposome, LEP-ETU
BI 695500,
C2B8 Monoclonal Antibody,
CT-P10,
IDEC-C2B8 monoclonal antibody,
rituximab biosimilar ABP 798,
rituximab biosimilar BI 695500,
rituximab biosimilar GB241,
rituximab biosimilar HLX01,
rituximab biosimilar IBI301,
rituximab biosimilar PF-05280586,
rituximab biosimilar Reditux,
rituximab biosimilar RTXM83,
rituximab biosimilar SAIT101, Rituxan
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CDDP, DDP

MOAB IDECC2B8

methylprednisolone

steroid

methylprednisolone acetate,
methylprednisolone succinate,
methylprednisolonum, Depo-Medrol,
Medlone 21,
Medrol,
Meprolone,
Metrocort,
Metypred,
Solu-Medrol,
Summicort

MePRDL

docetaxel

taxane

Docefrez,
Taxotere,
Taxotere injection concentrate

TXT

leucovorin

chemoprotectant

leucovorin calcium, calcium (6S)-folinate,
calcium folinate,
CFR,
citrovorum factor,
folinate calcium,
folinic acid,
Folinic Acid Calcium Salt Pentahydrate,
Leucovorin,
LV, Wellcovorin

CF

bendamustine

alkalatingAgent

bendamustin hydrochloride, CEP-18083,
cytostasan hydrochloride, Treanda

SDX-105

everolimus
melphalan

mTORInhibitor
alkalatingAgent

42-O-(2-hydroxy)ethyl rapamycin, Afinitor, Zortress
L-PAM
L-phenylalanine mustard,
L-sarcolysin,
L-sarcolysin phenylalanine mustard,
L-sarcolysine,
phenylalanine mustard,
phenylalanine nitrogen mustard,
sarcoclorin, Alkeran

RAD001
CB-3025,
WR-19813

daunorubicin

anthracycline

FI-6339,
RP-13057

busulfan

alkylatingAgent

daunorubicin hydrochloride, cloridrato de
daunorubicina,
daunoblastine,
daunomycin hydrochloride,
rubidomycin hydrochloride, Cerubidine
BSF,
Bussulfam,
Busulfanum,
busulphan,
glyzophrol,
methanesulfonic acid, tetramethylene ester,
Myeleukon,
Myeloleukon,
Myelosan,
Mylecytan,
Sulfabutin,
tetramethylene
bis(methanesulfonate),Busulfex
Myleran

sirolimus

mTORInhibitor

rapamycin, Rapamune

dasatinib

tyrosineKinaseInhibitor

Sprycel

RP 56976

BU,
BUS

CB-2041,
GT-41,
WR-19508

RAPA,
SLM

AY 22989,
SILA 9268A,
WY-090217
BMS-354825
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sorafenib
vinorelbine

tyrosineKinaseInhibitor
plantAlkaloid

sorafenib tosylate, Nexavar
vinorelbine tartrate, navelbine ditartrate,
vinorelbine ditartrate, Navelbine

SFN
NVB

BAY 54-9085
KW-2307

ifosfamide

alkalatingAgent

Ifomide,
Iphosphamid,
iphosphamide,
Isoendoxan,
Iso-Endoxan,
isophosphamide,
Naxamide, Cyfos,
Ifex,
Ifosfamidum

IFF,
IFO,
IFX,
IPP

Asta Z-4942,
MJF-9325,
Z-4942

carboplatin

platinum

Carboplatin Hexal,
Carboplatino

CBDCA

JM-8

ixabepilone

antimicrotubuleAgent

Azaepothilone B,
epothilone B lactam,
Epothilone-B BMS 247550, Ixempra

asparaginase

enzyme

ASP-1,
asparaginase II,
Colaspase,
L-ASP,
L-asparaginase,
L-asparagine amidohydrolase,Elspar,
L-Asnase

L-ASP,
Lcf-ASP

MK-965,
Re-82-TAD-15

mercaptopurine

antimetabolite

6 thiohypoxanthine,
6 thiopurine,
6-mercaptopurine,
6-mercaptopurine monohydrate,
6-purinethiol,
6-thiopurine,
6-thioxopurine,
Azathiopurine,
Leupurin,
Mercapurin,
Mern,
Purimethol, Purinethol,
Purixan

6-MP,
MP

BW 57-323H,
U-4748,
WR-2785

bortezomib

proteasomeInhibitor

PS-341, VELCADE

temozolomide

alkylatingAgent

Methazolastone,
Temodar

TMZ

pegaspargase

enzyme

L-asparaginase with polyethylene glycol,
PEG-asparaginase,
PEG-L-asparaginase,
PEG-L-asparaginase(K-H),
polyethylene glycol-L-asparaginase,Oncaspar

PEG-ASP,
PEGLA
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BMS-247550

LDP 341,
MLN341,
PS-341

CCRG-81045,
M & B 39831,
RP-46161,
SCH 52365

fluorouracil

antimetabolite

5-fluorouracil injection,
5-Fluracil,
fluouracil,
Fluracil,

5-FU injection,
FU

Ro-2-9757

carmustine

alkylatingAgent

bis(chloroethyl) nitrosourea,
bis-chloronitrosourea,
carmustin,Becenum,
BiCNU,
Carmubris

BCNU

FDA 0345,
SK 27702,
SRI 1720,
WR-139021

oxaliplatin

platinum

Ai Heng,
Aiheng,
diaminocyclohexane oxalatoplatinum,
oxalatoplatin,
oxalatoplatinum,
oxaliplatine, Eloxatin

1-OHP,
L-OHP

JM-83,
RP-54780,
SR-96669

lapatinib

tyrosineKinaseInhibitor

lapatinib ditosylate, Tykerb

selumetinib

tyrosineKinaseInhibitor

mitoxantrone

anthracycline

bevacizumab

monoclonalAB

GSK572016,
GW2016,
GW-572016
ARRY-142886,
AZD6244

mitoxantrone
hydrochloride,dihydroxyanthracenedione,
dihydroxyanthracenedione dihydrochloride,
mitoxantrone dihydrochloride,
mitoxantrone HCl,
mitozantrone,
anti-VEGF humanized monoclonal antibody,
anti-VEGF monoclonal antibody,
anti-VEGF rhuMAb,
bevacizumab biosimilar BEVZ92,
bevacizumab biosimilar BI 695502,
bevacizumab biosimilar CBT 124,
bevacizumab biosimilar FKB238,
bevacizumab biosimilar PF-06439535,
immunoglobulin G1 (human-mouse
monoclonal rhuMab-VEGF gamma-chain
anti-human vascular endothelial growth
factor), disulfide with human-mouse
monoclonal rhuMab-VEGF light chain, dimer
recombinant humanized anti-VEGF
monoclonal antibody,
rhuMAb VEGF, Avastin,
Mvasi

81

DHAD,
DHAQ

rhuMAb VEGF,
rhuMab-VEGF

CL 232315

hydrocortisone

steroid

Barseb-HC,
Cortifan,
cortisol,
Domolene,
Komed-HC,Aeroseb-HC,
Barseb HC,
Cetacort,
Cort-Dome,
Cortef,
Cortenema,
Cortispray,
Cortril,
Dermacort,
Domolene-HC,
Eldecort,
Hydrocortone,
Hytone,
Komed HC,
Nutracort,
Proctocort,
Rectoid

HC

gemcitabine
irinotecan

antimetabolite
topoisomeraseInhibitor

azacitidine

antimetabolite

alvocidib

kinaseInhibitor

gemcitabine hydrochloride,
irinotecan hydrochloride, camptothecin-11,
irinotecan, irinotecan HCl, Camptosar
5-AC, 5-azacytidine, azacytidine,
ladakamycin, Mylosar, Vidaza
Afinitor, Zortress

dFdCyd
CPT-11, U101440E
5-AC, 5-AZC,
AZA-CR
RAD001

prednisolone

steroid

octreotide

hormone

octreotide pamoate

hormone

vorinostat

statin

suberoylanilide hydroxamic acid, Zolinza

SAHA

idarubicin

histoneDecetylaseInhibitor

4-DMDR, IDA

dacomitinib

tyrosineKinaseInhibitor

idarubicin hydrochloride, 4demethoxydaunomycin, 4demethoxydaunorubicin, DMDR, idarubicin
HCl, Idamycin
EGFR inhibitor PF-00299804,

thiotepa

alkylatingAgent

TSPA

decitabine

hypomethylatingAgent

erlotinib

tyrosineKinaseInhibitor

thiofosfamide, thiophosphamide,
thiophosphoramide, triethylene
thiophosphoramide
5-aza-dCyd, deoxyazacytidine, dezocitidine,
Dacogen
Tarceva

lenalidomide

immunomodulatoryAgent

IMiD-1, Revlimid

gemtuzumab
ozogamicin

monoclonalAB

gemtuzumab ozogamicin, CalicheamicinConjugated Humanized Anti-CD33
Monoclonal Antibody
hP67.6-Calicheamicin, Mylotarg

delta(1)hydrocortisone, delta1-dehydroPRDL
hydrocortisone, deltahydrocortisone,
metacortandralone, Cortalone, Delta-Cortef,
Hydeltra, Hydeltrasol, Meti-derm, Prelone
octreotide acetate, Longastatin, Sandostatin, Sandostatin Lar
Depot,
ctreotide pamoate LAR(SMS 201-995), OP LAR, OncoLAR,
Sandostatin pamoate, Sandostatin pamoate LAR
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U-18496

SMS 201-995
SMS 201-995 pa,
SMS 201-995 pa
LAR
L-001079038,
MSK390
IMI-30, SC33428

PF-00299804,
PF-0029980403
WR-45312

5AZA, DAC
CP-358,774,
CP358774,
OSI774, OSI774
CC-5013, CDC
501
CDP-771, CMA676, WAY-CMA676

pemetrexed

antimetabolite

topotecan
pomalidomide
thymocyte

topoisomeraseInhibitor
immunomodulatoryAgent
antithymocyte

capecitabine
imatinib

antimetabolite
tyrosineKinaseInhibitor

nilotinib
belinostat

tyrosineKinaseInhibitor
histoneDecetylaseInhibitor

thioguanine

antimetabolite

zibotentan
ipilimumab

other
monoclonalAB

dacarbazine

alkylatingAgent

ganetespib

other

temsirolimus
gefitinib
paclitaxel albuminstabilized
nanoparticle
formulation

mTORInhibitor
tyrosineKinaseInhibitor
plantAlkaloid

cell cycle inhibitor 779, rapamycin analog CCI-779, Torisel
Iressa
albumin-bound paclitaxel,
Albumin-Stabilized Nanoparticle Paclitaxel,
nab paclitaxel,
nab-paclitaxel,
nanoparticle albumin-bound paclitaxel,
Nanoparticle Paclitaxel,
protein-bound paclitaxel, Abraxane

CCI-779
ZD 1839
ABI-007

eribulin

microtubuleInhibitor

halichrondrin B analog, Halaven

B1939 mesylate,
E7389,
ER-086526

cediranib
entinostat
lomustine

tyrosineKinaseInhibitor
histoneDecetylaseInhibitor
alkylatingAgent

AZD2171 maleate, Recentin
HDAC inhibitor
Lomustinum, Gleostine

AZD2171

thalidomide

immunomodulatoryAgent

alpha-phthalimidoglutarimide,
N-phthaloylglutamimide,
N-phthalylglutamic acid imide, Thalomid

arsenic trioxide

other

arsenic trioxide formulation ORH 2014,
As2O3 formulation ORH 2014,
oral arsenic trioxide formulation

tretinoin

other

liposomal tretinoin, All-trans-retinoic acid
liposomal,
tretinoin liposomal,
tretinoin liposome,
tretinoinLF, Atragen

pemetrexed disodium, multitargeted
MTA
LY231514
antifolate, Alimta
liposomal topotecan hydrochloride, topotecan hydrochloride liposomes, Brakiva
Pomalyst
CC-4047
anti-thymocyte globulin, lymphocyte
ATG
immune globulin, ATGAM, Thymoglobulin
Xeloda
CAPE
Ro 09-1978/000
imatinib mesylate, Gleevec
CGP 57148,
CGP57148B, STI571
Tasigna
AMN 107
Beleodaq
PXD 101,
PXD101
tioguanin, tioguanine, Tabloid
6-TG, TG
BW 5071,
Wellcome, U3B,
WR-1141, X 27
ZD4054
anti-cytotoxic T-lymphocyte-associated
MDX-CTLA-4
BMS-734016,
antigen-4 monoclonal antibody, MOAB
MDX-010
CTLA-4, monoclonal antibody CTLA-4, Yervoy
Biocarbazine, Dacarbazina, Dacarbazina
DIC, DTIC
WR-139007
Almirall, Dacarbazine - DTIC, Dakarbazin,
Dimethyl (triazeno) imidazolecarboxamide,
Dimethyl Triazeno Imidazol Carboxamide,
Dimethyl Triazeno Imidazole Carboxamide,
Imidazole Carboxamide,
Imidazole Carboxamide Dimethyltriazeno,
DTIC-Dome
Hsp90 inhibitor STA-9090
STA-9090
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CCNU

RB-1509, WR139017

THAL

ORH-2014

L-ATRA

AR-623

chlorambucil

alkylatingAgent

chlorambucilum,
chloraminophen,
Chlorbutin,
chlorbutine,
chlorbutinum,
chloroambucil,
chlorobutin,
chlorobutine,
Leukersan,
Leukoran,
Lympholysin,
phenylbutyric acid nitrogen mustard,
Ambochlorin, Amoclorin, Leukeran, Linfolizin

afimoxifene

hormoneInhibitor

4-Hydroxy-Tamoxifen

tamoxifen

hormoneInhibitor

trabectedin
cabozantinib
ramucirumab

monoclonalAB

cabazitaxel

taxane

nivolumab

monoclonalAB

anti-PD-1 human monoclonal antibody MDX1106, Opdivo, Opdivo Injection

romidepsin

histoneDecetylaseInhibitor

depsipeptide, Istodax

amifostine

other

APAETP

WR 2721,
WR2721,
WR-2721,
YM-08310

sunitinib

tyrosineKinaseInhibitor

amifostine trihydrate,
aminopropylaminoethylthiophosphoric acid
trihydrate,
ethiofos,
gammaphos, Ethyol
sunitinib malate, Sutent

SU11248

SU011248,
SU011248,
SU11248

panitumumab

monoclonalAB

clone E7.6.3,
monoclonal antibody ABX-EGF, Vectibix

MOAB ABX-EGF

ABX-EGF

pazopanib

tyrosineKinaseInhibitor

pazopanib hydrochloride, Votrient

thioplex

alkylatingAgent

TSPA

alemtuzumab

monoclonalAB

thiotepa, thiofosfamide, thiophosphamide,
thiophosphoramide, triethylene
thiophosphoramide
anti-CD52 monoclonal antibody,
Campath-1H,
Monoclonal Antibody Campath-1H,
Monoclonal Antibody CD52, Campath

muromonab

monoclonalAB

MOAB OKT3

ofatumumab

monoclonalAB

muromonab-CD3, Anti-CD3 monoclonal
antibody OKT3,
MOAB OKT3,
monoclonal antibody OKT3,
OKT3, Orthoclone OKT3
Arzerra

pravastatin*

statin

pravastatin sodium, Pravachol

PRAV

CHL, CLB

CB-1348, WR139013

tamoxifen citrate, tamoxifeni citras,
Nolvadex

TAM

ICI 46,474,
ICI-46474

alkylatingAgent

ecteinascidin, Yondelis

ET 743

tyrosineKinaseInhibitor

cabozantinib-s-malate, Cabometyx,
Cometriq
anti-VEGFR-2 fully human monoclonal
antibody IMC-1121B, Cyramza
taxoid XRP6258, Jevtana
NIVO

FK228,
FR901228,
NSC 630176

GW786034B
WR 45312

MoAb CD52

2F2,
GSK1841157

*pravastatin sodium has potential antineoplastic activities
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BMS-907351, XL
184
IMC-1121B,
LY3009806
RPR-116258A,
XRP6258
BMS-936558,
MDX-1106,
ONO-4538

Appendix B. Curriculum Vitae
Christina Eldredge, MD, MSMI
HOME ADDRESS:
17230 Emerald Chase Drive
Tampa, Florida 33647
PHONE: 847-909-6320
EMAIL: work: celdredge2@usf.edu
CITIZENSHIP: U.S.A
EDUCATION:
9/1988 – 5/1992 – B.S., Biology, University of Miami Biology, Coral Gables, FL
7/1992 - 6/1996 – M.D., University of Miami School of Medicine, Miami, FL
9/2008 – 2/2013 – MSMI, Medical College of Wisconsin/Milwaukee School of
Engineering, Milwaukee, WI
1/2013 – 5/2020 – Biomedical and Health Informatics Doctorate Program, University of
Wisconsin-Milwaukee, Milwaukee, WI
POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
7/1996 - 6/1999 - Medical College of Wisconsin, Columbia Family Practice Residency
Program, Milwaukee, WI
6/2010 - 5/2013- Academic Fellowship in Primary Care Research, Medical College of
Wisconsin, Milwaukee, WI
9/2018-11/2018- NSF I-Corps Fellow, University of South Florida, Tampa, FL
MILITARY SERVICE:
7/1999 – 12/2003 – Family Medicine Physician, Lieutenant Commander, Medical
Corps, U.S. Naval Hospital Great Lakes, Great Lakes, IL
FACULTY APPOINTMENTS:
6/2010 – 5/2013 – Fellow/Instructor, Academic Fellowship in Primary Care Research,
Department of Family and Community Medicine, Medical College of Wisconsin,
Milwaukee, Wisconsin
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6/2013-5/2015- Clinical Instructor, Department of Family and Community Medicine,
Medical College of Wisconsin, Milwaukee, Wisconsin
10/2014-12/2018-Adjunct Assistant Professor, University of Wisconsin-Milwaukee,
Department of Health Informatics and Administration, Milwaukee, Wisconsin
1/2017-7/2017-Adjunct Instructor, University of South Florida, College of Arts &
Sciences, School of Information, Tampa, Florida
8/2017-present-Visiting Instructor, University of South Florida, College of Arts &
Sciences, School of Information, Tampa, Florida
3/2019-present-Adjunct Professor, Department of Molecular Medicine, Morsani College
of Medicine, University of South Florida, Tampa, Florida
SPECIALTY BOARD AND CERTIFICATIONS:
Board Certified
American Board of Family Medicine
Licensure
Number
Wisconsin License
39039
Licensure
Number
Florida License
ME 136748

Issue Date
1999
Issue Date
1997
Issue Date
2018

Expiration
12/31/2025
Expiration
10/31/2021
Expiration
01/31/2022

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES
2011 – 2013
Wisconsin Public Health Association
1994 – Present
Academy of Family Physicians
1995 – Present
Alpha Omega Alpha National Medical Honor Society
2011 – Present
American Medical Informatics Association (AMIA)
2018 – Present
Health Information and Management Systems Society (HIMSS)
AWARDS AND HONORS:
1994 University of Miami School of Medicine CIBA Award for Community Service
1995 Alpha Omega Alpha National Honor Medical Society (Officer 1995-1996)
2003 Navy and Marine Corps Achievement Medal for superior performance as one of
three physicians to initiate the Family Practice Clinic at Naval Hospital Great Lakes
2012 Outstanding Medical Student Teacher Award from the Medical College of
Wisconsin for Medical Interviewing
EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:
Journal Review
2011-2015
Journal of School Health
2014-present Wisconsin Medical Journal
2014-present American Medical Informatics Association
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INTERNATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE
POSITIONS:
10/2011 Track Co-Chair, ISCRAM, International Conference on Information
Systems for Crisis Response and Management, Healthcare Crisis Management
Systems Track
LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
1999 – 2002 Peer Review Coordinator, Family Practice Department, U.S. Naval Hospital
Great Lakes, Great Lakes, IL
2001 – 2003 Member, Naval Dental and Biomedical Research Institutional Review
Board, US Great Lakes Naval Base, Great Lakes, IL
2012 – 2015 Member, Archdiocese of Milwaukee Office for Schools Health and
Wellness Steering Committee
2012 – 2015 St. Anthony School’s Padre Pio Clinic Board of Directors
Advisory Board (IAB)
2020-present Member, Information Day Planning Committee, iSchool, USF

NATIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
2015
Member, Multidisciplinary Anaphylaxis Advisory Board for Mylan
Specialties, the maker of EpiPen®, April 17-18, 2015 in Canonsburg, PA
2015
University of Wisconsin-Milwaukee Representative, Academic Forum for the
American Medical Informatics Association (AMIA). Participated at the
national level in health informatics curriculum development.
2015-2019
Member, AMIA Health Informatics Accreditation Committee
2019-present Member, HIMSS Professional Development Committee
2020-present Member, AMIA Educational Committee
RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:
Peer Review
Title: NSF 14-547 PI: Paul Sandberg 04/01/2015 to 03/31/2019 Funding: $296,
435 INNOVATION CORPS (I-CORPS) SITES PROGRAM
Source: NSF
Role: I-Corps Fellow
Dates: Fall 2018
Title: Advancing Community-Partnerships for Translational Research: Scientific
Citizens and Citizen Scientists
Source: Advancing a Healthier Wisconsin Endowment
Role: Faculty
Dates: 7/1/2010 – 6/30/2015
Direct Funds: $1,659,180
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Title: Healthier Obstetrical Outcomes through Enrichment Activities and
Community Engagement
Source: HWPP
Role: Co-Investigator
Dates: 1/1/2014-12/31/2015
Requested Funds: approx. $200,000
Title: Teleophthalmology to Improve Eye Health among Latinos (TIEHL):
UCC-MCW-Marquette Collaboration
Source: HWPP
Role: Co-Investigator
Dates: 1/1/2014-6/30/2015
Requested Funds: approx. $200,000
Title: mPeer: Mobile Detection of High Risk Behavior in Veterans - A
Sociotechnical Systems Approach
Source: Clinical and Translational Science Institute (CTSI)
Role: Co-investigator
Dates: 3/1/2013 - 11/1/2013
Direct Funds: $50,000 over 1 year
INVITED LECTURES/WORKSHOPS/PRESENTATIONS:
Speaker, “Applied Health Informatics Master’s Level Education: A Discussion of Core
Competencies”, HIMSS20 Lightening Session, occurring March 12, 2020.

Keynote Speaker, “Connected Health: How your smartphone can manage your health”,
Information Day, University of South Florida School of Information
April 25, 2018.
Pediatric Food Allergy Management in the Community. CME Presentation. The Medical
College of Wisconsin Department of Family and Community Medicine’s 45nd Annual
Winter Refresher Course for Family Medicine. Waukesha, WI, January 30, 2015.
Guest Lecturer, Translational Science and Translational Biomedical Informatics,
Milwaukee School of Engineering Biomolecular Engineering (BioE) Program
Seminar Course, January 13th, 2015
2014 Catholic Educators Convention, Leading the Learning
Presented: Food Allergy Update
Frontier Airlines Center, Milwaukee, October 10th, 2014.
Guest Lecturer, Clinical Research Informatics Case Presentation,
Milwaukee School of Engineering Medical Informatics Case Study Course: September
19th, 2013, MSOE, Milwaukee, WI, September 15th, 2014, MSOE, Milwaukee, WI,
October 22nd, 2015, MSOE, Milwaukee, WI

88

mHealth: Using Mobile Technology to Connect with Your Patient. The Medical College
of Wisconsin Department of Family and Community Medicine’s 44nd Annual Winter
Refresher Course for Family Medicine. Waukesha, WI. February 5th, 2014.
2012 Catholic Educators Convention, Catholic Schools: A Commitment to Excellence
Presented: Managing Food Allergies in the Classroom
Frontier Airlines Center, Milwaukee, October 12th, 2012.
Facilitator, Community Health Informatics Workshop, Information Technology
Resources for Research Breakout Session, University of Wisconsin-Milwaukee School of
Continuing Education Conference Center, Tuesday October 2, 2012, Milwaukee, WI.
Pediatric Food Allergy: School-Based Management. CME Presentation. The Medical
College of Wisconsin Department of Family and Community Medicine’s 42nd Annual
Winter Refresher Course for Family Medicine. Waukesha, WI. February 3rd, 2012.

PEER REVIEWED PRESENTATIONS
Poster presentations
Local
Golam M. Tanimul Ahsan, Christina Eldredge, MD MS; Brenda White, EdS; Zeno
Franco, PhD; Sheikh I. Ahamed, PhD. mHealth for School Emergency Preparedness.
Clinical & Translational Science Institute of Southeast Wisconsin’s Community Health
Informatics Workshop, Milwaukee, WI, May 30, 2013.
Eldredge CE, Patterson L, Schellhase K. Implementation of Food Allergy Management
Policies in Private Schools. 20th Annual Department of Family and Community
Medicine Research Forum. Medical College of Wisconsin, Milwaukee, WI, May 23rd,
2011.
Regional
Patterson L, Morzinski J, Eldredge CE. Using Veterans as Peer-Group Health Workers
to Improve Hypertension Awareness and Management. 2011 Wisconsin Public Health
Association and Wisconsin Association of Local Health Departments and Boards Annual
Conference, “Healthiest State in One Generation”. Appleton, WI, May 24-26, 2011.

National
Eldredge C., Andrews J.E., Zolnoori M., Patrick T., Gallagher J., Lam C. and J. Luo.
Challenges to a Data Driven Approach to Population Level Analysis of Hypersensitivity
Events in Cancer Clinical Trials. Poster presented at the AMIA Annual Symposium,
November 19, 2019, Washington, D.C.
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Lam C., Eldredge C., Andrews J., Perkins R. Challenges to Data Abstraction to
Characterize Contrast Media Reactions and Identify Potential Risk Factors in a Cancer
Patient Population. Poster presented at the AMIA Annual Symposium, November 19,
2019, Washington, D.C.
Lam C., Eldredge C., Andrews J.E. and Perkins R. Adverse Contrast Media Event
Documentation: A Cancer Center Perspective. Poster presented at the AMIA Clinical
Informatics Conference, April 30 – May 2, 2019, Atlanta, GA.
Andrews J.E., Eldredge C, and Cooperman C. Building an Institute for Health Sciences
Information (Ihsi): Connecting Education, Industry, and Research. Accepted to the
AMIA InSpire 2017: Developing the Health Informatics Workforce of the Future
conference, La Jolla, CA, June 6-8, 2017.
Joel Gallagher; Robert Rivera; Asriani Chiu; Tanvir Roushan; Golam Mushih Tanimul
Ahsan; Cheng Wen; Christina Eldredge; Sheikh Iqbal Ahamed. “The Use of a mHealth
Decision Tree Support Program for Epinephrine Auto-injector (EAI) Administration
Training of Adolescents” AMIA 2016 Annual Symposium Conference Proceedings,
Washington DC, Nov. 15, 2016.
Eldredge, Christina; Ahsan, Golam Mushih Tanimul; Chiu, Asriani; White, Brenda;
Atchison, Taylor; Patterson, Leslie; Ahamed, Sheikh Iqbal. “Pilot assessment of a
caregiver decision support mobile health (mHealth) application for food allergy &
anaphylaxis in the school environment.” AMIA 2014 Annual Symposium Conference
Proceedings, Washington DC, Nov. 15-19, 2014.
Christina Eldredge, MD MS; Golam M Tanimul Ahsan; Zeno Franco, PhD; Brenda
White, Ed.S.; Asriani M. Chiu, MD; Leslie Patterson, PhD MS; Mohammad Arif Ul
Alam; Sheikh Iqbal Ahamed, PhD. mHealth for School Food Allergy Emergency
Preparedness. mHealth Summit. Washington D.C. December 2013.
Slawson J, Eldredge CE, Hughes J, Payne J, Olsen S, Leienger M. Benefits of a Patient
Centered Medical Home for High Risk OB Care: A first year preliminary report. 5th
Annual National CTSA Community Engagement Conference, “Methods, Metrics and
outcomes: Evaluating the Success of Community Engaged Research”, Bethesda, MD,
August 23rd-24th, 2012.
Eldredge CE, Slawson J, Granados R, Payne J. Developing a Combined Research and
QI Database from Community Based Practices with Different IT Systems. 4th Annual
National CTSA Community Engagement Conference, “Using IT to Improve Community
Health: How Health Care Reform Supports Innovation”. Bethesda, MD, August 30th31st, 2011.
Morzinski J., Patterson L., Eldredge CE. Teaching Community Health Workers to Train
Peers About Hypertension: Outcomes & Implications. Society of Teachers of Family
Medicine Spring Conference, New Orleans, LA, April 2011.
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Educational Exhibits/Workshops
Zolnoori, M., Patrick, T. B., Fung, KW., Fontelo P., Faiola, A., Wu YS. S., Xu, K., Zhu,
J., Eldredge, C. E. Development of an Adverse Drug Reaction Corpus from Consumer
Health Posts. Workshop: American Medical Informatics Association, Annual Symposium,
Washington, DC., November, 2017. http://ceur-ws.org/Vol-1996/paper3.pdf
Lam CA, Eldredge C, Taylor B, Ahmed N, Kahn C. Feasibility of a Generalized
Informatics Framework for Cohort Identification, Hypothesis Generation, and
Retrospective Data Analysis for Radiology Research - Educational Exhibit. Chicago, IL,
Radiological Society of North American (RSNA) Meeting 2013.

National Oral Presentations
Zolnoori M., Ngufor C., Faiola A., Eldredge C., Luo J., Sunghwan S., Balls-Berry J.E.,
Tafi A.P., Shah N.D., Patrick T.B. Identifying Factors Affecting Drug Discontinuation in
Patients with Depression: Text Analysis of Patient Drug Review Post. Podium Abstract
presented at the AMIA Annual Symposium, November 19, 2019, Washington, D.C.
Eldredge C, Singavi A, Lam C, Gallagher J and Luo J. Big Data Analysis of Drug
Induced Hypersensitivity and Anaphylaxis Reactions in Clinical Cancer Trails.
AAAAI/WAO, Orlando, FL, March 3, 2018. Journal of Allergy and Clinical
Immunology, Vol 141, Issue 2, Supplement, Page AB87.
Lam CA, Eldredge C, Sawlani R, Bushee G, Taylor B, Kahn C. Assessing the Validity of
Contrast Induced Nephropathy Using the i2b2 Informatics Framework: A Retrospective
3-year Electronic Medical Record Review. Oral Paper Presentation. Chicago, IL, RSNA
2014.
MEDICAL COLLEGE TEACHING ACTIVITIES:
Community/Lay Public
2011 Archdiocese of Milwaukee School Staff Medication Training Day
Medical Student Education
2012-2014 Instructor, M1 Foundations of Clinical Medicine course
2011-2014 Instructor, CHCR Family Medicine Clerkship
2011-2012 Instructor, Medical Interviewing
2010-2013 Facilitator, Medical Student Intercessions
2010-2013 Facilitator, Urban and Community Health Pathway
STUDENTS, FACULTY, RESIDENTS AND CLINICAL/RESEARCH FELLOWS
MENTORED:
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Medical Students:
6/2012 – 9/2012 Medical College of Wisconsin, M2 Summer Research Internship Student
9/2011 – 5/2014 Medical College of Wisconsin, Urban and Community Pathway Student
9/2012 – 5/2018 Medical College of Wisconsin, Quality Improvement Pathway Students
Masters Students and Fellows:
2014 – 2015
Marquette Computer Science Student, member of Masters’ Thesis
Committee
2014 – 2017
Medical College of Wisconsin Allergy and Immunology Fellow,
member of his Scholarly Oversight Committee and mentor for a mobile
health project
2016 - 2018
Medical College of Wisconsin, Hematology and Oncology Fellow,
mentor in Health Informatics
PUBLICATIONS:
Maryam Zolnoori; Kin Wah Fung; Timothy Patrick; Paul Fontelo; Hadi Kharrazi;
Anthony Faiola; Yi Shuan Shirley Wu; Christina E. Eldredge; Jake Luo; Mike Conway;
Jiaxi Zhu; Soo Kyung Park; Kelly Xu; Hamideh Moayyed. (2019, March 21). The PsyTAR
Dataset: From Patients Generated Narratives to a Corpus of Adverse Drug Events and
effectiveness of Psychiatric Medications. Data in brief. 24:103838. PMID: 31065579
Maryam Zolnoori; Kin Wah Fung; Timothy Patrick; Paul Fontelo; Hadi Kharrazi;
Anthony Faiola; Yi Shuan Shirley Wu; Christina E. Eldredge; Jake Luo; Mike Conway;
Jiaxi Zhu; Soo Kyung Park; Kelly Xu; Hamideh Moayyed; Somaieh Goudarzvand. (2019, Jan 3)
A Systematic Approach for Developing a Corpus of Patient Reported Adverse Drug Events: A
Case Study for SSRI and SNRI Medications. Journal of Biomedical Informatics. PMID:
30611893
Annette L Valenta, Eta S Berner, Suzanne A Boren, Gloria J Deckard, Christina Eldredge,
Douglas B Fridsma, Cynthia Gadd, Yang Gong, Todd Johnson, Josette Jones, E LaVerne Manos,
Kirk T Phillips, Nancy K Roderer, Douglas Rosendale, Anne M Turner, Guenter Tusch, Jeffrey J
Williamson, Stephen B Johnson. (2018, Dec. 1) AMIA Board White Paper: AMIA 2017 core
competencies for applied health informatics education at the master’s degree level. Journal of
the American Medical Informatics Association, 25 (12): 1657-1668. PMID: 30371862
Gallagher JL, Rivera RD, Van Shepard K, Roushan T, Ahsan G, Ahamed SI, Chiu A, Jurken M,
Simpson PM, Nugent M, Gobin KS, Wen CKF, and Eldredge CE. (2018, Jul 3). LifeThreatening Allergies: Using a Patient-Engaged Approach. Telemedicine Journal and e-Health.
PMID: 29969372
Luo J, Eldredge C, Cho CC, Cisler RA. (2016) Population Analysis of Adverse Events in
Different Age Groups Using Big Clinical Trials Data. JMIR Med Inform, 4(4): e30. PMID:
27751983
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Jackson J, Cogbill E, Santana-Davila R, Eldredge C, William C, Gradell A, Sehgal N, Kuester J.
(2015, Jul 14) A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of
Migraine Headache. PLOS ONE, 10(7): E0130733. PMID: 26172390
Eldredge C, Patterson L, White B, Schellhase K. (2014, Aug) Assessing the Readiness of a
School System to Adopt Food Allergy Management Guidelines. Wisconsin Medical Journal, 113
(4); 155-161. PMID: 25211803
Bradford L, Eldredge CE, Morzinski, JA. (2013, Feb) Training community-engaged
researchers. Academic Medicine, 88(2):154. PMID: 23361025
Eldredge CE and Schellhase K. (2012, Jul 1) School-Based Management of Food Allergies in
Children. American Family Physician, 86(1), 16-18. PMID: 22962908
Marriott LK, Nelson DA, Allen S, Allen, S. Calhoun, K. Eldredge CE. Kimminau KS. Lucero
RJ. Pineda-Reyes F. Rumala BB, Varanasi, AP, Wasser, JS, Shannon J. (2012, Feb. 1) Using
health information technology to engage communities in health, education, and research. Science
Translational Medicine, 4(119), 119mr111. PMID: 22301550
Kahn CE, Jr., Kalpathy-Cramer J, Lam CA, Eldredge CE. Accurate Determination of Imaging
Modality using an Ensemble of Text- and Image-Based Classifiers. (2011, Jul 6) Journal of
Digital Imaging, 25(1), 37-42. PMID: 21748413
Book Chapter
Andrews, J. E., Johnson, J.D., & Eldredge, C. (2019). The evolving roles of consumers. In R.
Richesson & J.E. Andrews (Eds). Clinical Research Informatics. Springer-Verlag: London 2nd
ed.
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